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The Effect of StarD13 on Colorectal Cancer 
Malignancy and Invasion 
 
Anita I. Nasrallah 
 
ABSTRACT 
 
 
Colon cancer is the cancer of the epithelial cells lining the colon. It is mainly divided 
into different stages according to invasiveness and metastatic ability of the tumor. 
Many mutations are acquired, leading to this malignancy. These occur in entities that 
greatly affect the cell cycle, cell signaling pathways, and cell movement, which all 
involve the action of Rho GTPases. The protein of our interest is DLC2, also known 
as StarD13 or START-GAP2, a GAP for Rho and Cdc42. Literature states that this 
protein is considered a tumor-suppressor in hepatocellular carcinoma. Previous work 
in our lab proved StarD13 to be a tumor suppressor in astrocytoma and in breast 
cancer. In this work, we studied the role of StarD13 in colon cancer. When 
overexpressed, StarD13 led to a decrease in cell proliferation in colon cancer cells. 
Consistently, knocking down StarD13 led to an increase in cell proliferation. This 
showed that, similarly to its role in astrocytoma and breast cancer, StarD13 seems to 
be a tumor suppressor in colon cancer as well. We were also interested in examining 
the role of StarD13 in cell motility. StarD13 knock down resulted in an inhibition of 
2D cell motility. This is due to the inhibition of Rho, thus Rac-dependant focal 
complexes are not formed nor detached for the cells to move forward. However, 
StarD13 knock down led to an increase in 3D cell motility. Although StarD13 was 
indeed a tumor suppressor in our colon cancer cells, as seen by its effect on cell 
proliferation, it was needed for cancer cell invasion. Our study further describes the 
role of StarD13 as a tumor suppressor as well as a RhoGAP. 
 
Keywords: StarD13, Colorectal Cancer, Cell Proliferation, Cell Motility, Cell 
invasion. 
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Chapter I 
LITERATURE REVIEW 
 
 
1.1. Colorectal Cancer 
1.1.1. Introduction 
 
Colorectal cancer, commonly known as bowel cancer, occurs in the 
colon, rectum, or appendix. Genetic analysis shows that tumors in these three 
locations are genetically of the same cancer (Cancer Genome Atlas Network, 
2012). Colorectal cancer is the second most commonly diagnosed cancer in 
females, the third in males (World Health Organization, 2010), and the forth 
around the world (Jemal, Bray, Center, Ward, & Forman, 2011). More than a 
million cases are yearly detected globally (Cunningham, et al., 2010). It is 
widespread in developed countries, where around 60% of the cases were 
diagnosed (Ferlay, et al., 2010), most of which lead to death (Merika, Saif, 
Katz, Syrigos, & Morse, 2010). 
There are several causes for the onset of colorectal cancers, which are 
nowadays better diagnosed and classified according to several criteria. 
Consistently, different treatments and prognostic measures are currently used 
to try and successfully cure this type of cancer (Cunningham, et al., 2010). 
 
1.1.2. Causes and predisposition 
 
Colorectal cancer occurs in a wide range of people. Most of them 
were previously, and might still be exposed to numerous risk factors. The rest 
are either genetically predisposed, or associated with other bowel diseases. 
1.1.2.1. Risk factors 
It is estimated that more than 80% of patients with colorectal 
cancer were exposed to a number of risk factors, such as male gender, 
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older age (Cunningham, et al., 2010), high intake of red meat or fat, 
smoking and obesity (Watson & Collins, 2011). The risk of alcohol 
increases at more than a drink per day (Fedirko, et al., 2011). Also, 
around 10% of these cases are related to insufficient activity (Lee, et al., 
2012). 
1.1.2.2. Genetics 
Around 18% of all cases are patients with a family history. Thus, 
they have a two to three-fold risk increase than other people. 
Furthermore, three main genetic diseases are well associated with this 
type of cancer. The most common is known as the Lynch syndrome, or 
the hereditary nonpolyposis colorectal cancer (HNPCC) (Cunningham, et 
al., 2010). Familial adenomatous polyposis (FAP) (Half, Bercovich, & 
Rozen, 2009) and Gardner syndrome (Juhn & Khachemoune, 2010) are 
both as well strongly associated with this type of cancer. 
1.1.2.3. Inflammatory Bowel Diseases 
A third cause is the incidence of the Inflammatory Bowel 
Diseases, such as ulcerative colitis and Crohn’s disease (Jawad, 
Direkzen, & Leedham, 2011). The longer the onset of these diseases (Xie 
& Itzkowitz, 2008), and the worse the inflammation (Triantafillidis, 
Nasioulas, & Kosmidids, 2009) will directly affect the risk of having 
colorectal cancer. However, only about 2% of this cancer is associated 
with the previously mentioned diseases (Jawad, Direkzen, & Leedham, 
2011). 
 
1.1.3. Pathogenesis 
 
Colorectal cancer originates from the epithelial lining, most often as a 
consequence of mutations in the Wnt signaling pathway. These mutations can 
be either acquired or inherited. They mostly occur in the intestinal gland stem 
cells (Ionov, Peinado, Malkhosyan, Shibata, & Perucho, 1993). 
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1.1.3.1. Tumor suppressor genes 
In all colorectal cancer, APC is the most commonly mutated gene. 
It produces the APC protein, which prevents the accumulation of the β-
catenin protein by binding to and degrading it. In the absence of APC 
protein, β-catenin highly accumulates in the cytoplasm, translocates to 
the nucleus, and binds to DNA, thus activating the transcription of 
several genes (Figure 1). These genes are responsible for stem cell 
renewal and differentiation. However, when improperly expressed at 
elevated levels they cause cancer (Markowitz & Bertagnolli, 2009). 
Some colorectal cancers have high β-catenin levels due to 
mutations in its gene CTNNB1, and not in the APC gene. These 
mutations block the degradation of β-catenin. Other colorectal cancers 
have mutations in other APC analogues, such as NKD1, TCF7L2, 
AXIN1, or AXIN2. Another tumor suppressor, PTEN, normally inhibits 
the overexpressed oncogene PI3K. However if PTEN is mutated, it 
becomes deactivated (Markowitz & Bertagnolli, 2009). 
 
 
Figure 1: Nuclear-cytoplasmic shuttling of β-catenin. In normal cells, β-catenin is 
(a) maintained on the membrane, in the nucleus, and in the cytoplasm, (b) bound to 
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APC in the cytoplasm then degraded, and (c) shuttling in the cytoplasm and nucleus. 
In tumor cells, β-catenin is found in very high abundance, moving between the 
nucleus and cytoplasm independent of its binding to APC. Thus no degradation 
occurs. Source: (Henderson & Fagotto, 2002) 
1.1.3.2. Apoptotic proteins 
Other than the defects mentioned above, additional mutations 
must take place for the cells to acquire more cancerous characteristics. 
One of these mutations occurs in the p53 protein, which is produced by 
the TP53 gene. This apoptotic protein monitors normal cell division. It 
kills the cells if they acquire any defect in the Wnt signaling pathway. Its 
mutation will change the tissue from a non-invasive adenoma into an 
invasive carcinoma (Chakravarthi, Krishnan, & Madhavan, 1999). In 
some cases, the gene encoding for BAX, another protective protein, is 
mutated, instead of the TP53 gene (Markowitz & Bertagnolli, 2009). 
Other apoptotic proteins are frequently mutated and deactivated in 
colorectal cancers. A major protein is the TGF-β, which in at least half of 
colorectal cancers has a deactivating mutation. In some cases, TGF-β is 
not the protein mutated, but its downstream protein SMAD (Markowitz 
& Bertagnolli, 2009). Another protein is the DCC protein, or Deleted in 
Colorectal Cancer. It acquires a deletion of its chromosomal segment 
(Mehlen & Fearon, 2004). 
1.1.3.3. Oncogenes 
Normal genes that encode proteins, known as oncoproteins, 
responsible for the regulation of cell growth and differentiation are 
known as proto-oncogenes. They are mainly involved in signal 
transduction. When activated, increased expression or mutations will 
result in the transformation into oncogenes, which are tumor-inducing 
agents (Chial, 2008). These are overexpressed in colorectal cancer, such 
as genes encoding the proteins PI3K, RAF, and RAS (Todd & Wong, 
1999). 
Under normal conditions and in response to growth factors, these 
proteins will stimulate the cell to divide. Acquired mutations will lead to 
the over-activation of cell proliferation. In some cases, the chronological 
order of mutations is crucial for the progression of cancer. To illustrate, if 
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at first a KRAS mutation occurred, this will lead to a self-limiting 
borderline lesion. On the other hand, if the KRAS mutation occurs after 
an APC mutation, it often leads to cancer (Vogelstein & Kinzler, 2004). 
All the previously discussed mutations occur in one type of colorectal 
carcinomas, known as the hypermutated tumor type. These tumors have 
mutated forms of BRAF, TCF7L2, SLC9A9, MSH3, MSH6, TGFBR2, and 
ACVR2A. Genome-scale analysis reveals that the non-hypermutated tumor 
type contains mutated ARIDIA, ATM, SOX9, and FAM123B. What is in 
common among the genes in both carcinomas is their involvement in the 
TGF-β and WNT signaling pathways. This, in turn, will result in the hyper 
activity of the central player in colorectal cancer, MYC (Cancer Genome 
Atlas Network, 2012).  
 
1.1.4. Classification of Colorectal Cancer 
 
The most widely used classification system is the TNM Staging 
System. It is considered the most descriptive and precise. T stands for the 
depth of the tumor, and to which level did it penetrate the colon wall. N refers 
to the involvement of lymph nodes. M stands for the degree of metastases that 
took place or whether the tumor has spread or not (Yarbro, Page, Fiedling, 
Partridge, & Murphy, 1999). 
Another less used system is the Duke’s system (Dukes, 1932). It was 
then modified and became the Modified Dukes Staging System. This system 
classifies the tumors under four main categories, i.e. A, B, C, and D. 
Modified Duke Stage A is the tumors that only reach the mucosal wall. B is 
the ones that penetrate through and out of the wall. C is the advancement of 
the tumor into the lymph nodes. D is when tumors are depicted in other 
organs, such as the liver, lung and bone (Astler & Coller, 1954). 
 
1.1.5. Symptoms and diagnosis 
 
Signs and symptoms of colorectal cancer greatly depend on its 
location and ability to metastasize. These include fever, loss of appetite, 
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weight loss, constipation, and blood in stool. In people older than fifty, 
common symptoms are nausea, vomiting anaemia, and rectal bleeding 
(Alpers, Kalloo, Owyang, Powell, & Kaplowitz, 2009). It is important to note 
that the most evident symptoms are weight loss and rectal bleeding (Astin, 
Griffin, Neal, Rose, & Hamilton, 2011). Without them all other symptoms 
can be indicative of several different gastrointestinal diseases (Adelstein, 
Macaskil, Chan, Katelaris, & Irwig, 2011). 
Colorectal cancers occurring on the right side of the colon, i.e. the 
ascending colon and cecum, usually cause severe fecal obstruction and 
anaemia. This is because these tumors tend to grow outward from a location 
of the bowel wall. However, left-sided tumors, i.e. tumors of the descending 
colon, cause constipation. These tumors are most likely circumferential 
(Jellema, et al., 2010). 
The first step towards diagnosis is to take tumor biopsy during wither 
colonoscopy or sigmoidoscopy. After confirming the presence of the cancer, 
imaging tests are performed of the patient’s chest, abdomen and pelvis, to 
determine the extent of the disease. These tests include CT scan, PET, and 
MRI. Based on these results, the physician can establish a clear idea of the 
stages of the cancer, depending on the TNM system of classification 
(Cunningham, et al., 2010). 
 
1.1.6. Pathology of the tumor 
 
After biopsy or surgery, a pathology report explicitly determines the 
cell type and grade of the tumor. In 95% of the cases, the colon cancer type is 
adenocarcinoma (Bafandeh, Khoshbaten, Eftekhar Sadat, & Farhanq, 2008). 
It originates from the glandular epithelium, invading the wall and infiltrating 
all layers. Tumor cells have irregular structures and might secrete mucus. 
Depending on the predominant cellular pleomorphism, gland architecture, 
and secretion of mucus, adenocarcinoma is separated into three differentiation 
levels: poorly, moderately, and well differentiated. Other than 
adenocarcinoma, rare types of colorectal cancer include squamous cell 
carcinoma and lymphoma (Danciu & Mihailovici, 2010). 
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Besides, the majority of colorectal cancer tumors are cyclooxygenase-
2, or COX-2, positive. This enzyme is abundantly found in cancerous tissue 
of the colon. It aids in abnormal cell growth (Tsujii, et al., 1998). 
1.1.7. Treatment and prognosis 
 
As any other type of cancer, the treatment of colorectal cancer 
depends on its advancement. At early stages, surgery is mostly curative. At 
later stages when the cancer is metastatic, physicians tend to treat their 
patients by trying to prolong their life and keep them comfortable (Stein, 
Atanackovic, & Bokemeyer, 2011). 
1.1.7.1. Surgery 
Patients with localized colorectal cancer undergo surgeries to 
extract the tumor. It is either done by laparotomy or laparoscopy, which 
is a minimally invasive procedure. If other tumors are metastasized to the 
lungs or liver, they are removed surgically (Cunningham, et al., 2010). 
1.1.7.2. Chemotherapy 
In some cases, chemotherapy is used before surgery. This will 
help shrink the tumor before eradicating it. In other cases where the 
cancer has metastasized and entered the lymph nodes, chemotherapy is a 
must to help increase the life expectancy of the patient. Drugs may 
include oxaliplatin, irinotecan, leucovorin, UFT, capecitabine, or 5-
fluorouracil. Monoclonal antibodies against molecular targets include 
cetuximab, panitumumab, or bevazicumab (Hoyle, et al., 2013). 
Understanding better the tumor biology and molecular pathways and 
mechanisms effectively led to the discovery of novel agents that 
specifically target molecular elements of cancer cells. This has helped 
improving the efficacy of drug-based chemotherapy that is nowadays 
combined with targeted monoclonal antibodies. Research is being 
extensively done to try and use cell signaling pathways as targets for 
colorectal cancer treatment, even though these pathways highly 
intercorrelate and crosstalk (Chung & Jang, 2013). 
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1.1.7.3. Radiation 
Combining chemotherapy and radiation might be helpful. But, in 
most cases, this is not used as curative technique, since the bowels are 
highly sensitive to radiation (Devita, Lawrence, & Rosenberg, 2008). 
1.1.7.4. Palliative care 
At the stage when colorectal cancer becomes incurable, the best 
remedy is to improve the quality of life by alleviating the symptoms and 
reducing the complications (Wasserberg & Kaufman, 2007). These 
procedures may include stent placement or bypassing part of the 
intestine, and pain medications. This will help reduce bleeding, intestinal 
obstruction, and abdominal pain (Amersi, Stamos, & Ko, 2004). 
 
Survival rates are directly linked to the type of cancer and its 
detection. Late stage cancers have five times less survival rates that early 
stage ones (Lin Koo, et al., 2013). To be on a safe side, follow-up is highly 
mandatory. This will help diagnose any new tumors that develop later, but 
had not originated from the original tumor (Simmonds, et al., 2006). Physical 
examinations are recommended, as well as blood tests and CT scans (Desch, 
et al., 2005). Close follow-up and intensive surveillance can reduce the five-
year mortality rate of patients with colorectal cancer from 37% to 30% 
(Figueredo, et al., 2003; Renehan, Egger, Saunders, & O'Dwyer, 2002). 
 
1.1.8. Prevention 
 
The most important ways to prevent colorectal cancer are a healthy 
lifestyle, appropriate medication, and continuous screening. 
 
1.1.8.1. Lifestyle 
Dietary recommendations include reducing the consumption of 
red meat and increasing the intake of fruits, vegetables, fibers and whole 
grains (Doyle, 2007). Physical activity also helps reducing the risk of 
colorectal cancer (Harriss, et al., 2009). 
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1.1.8.2. Medication 
People at high risk of having colorectal cancer are advised to take 
aspirin and celecoxib. They both appear to decrease the risk factor. 
Nevertheless, these drugs are not recommended to those at average risk 
(Cooper, et al., 2010). Vitamin D, especially its blood concentration, and 
Calcium intake are also associated with lower risks of colorectal cancer 
(Ma, et al., 2011; Yin, et al., 2011). 
1.1.8.3. Screening 
Several screening methods are applied nowadays, and they 
proved to be helpful in reducing death by the early detection (He & 
Efron, 2011). The three main tests are fecal occult blood testing of the 
stool, sigmoidoscopy, and colonoscopy (Qaseem, et al., 2012). The 
newest screening method is the M2-PK test to stool samples. The M2-PK 
enzyme biomarker is highly sensitive to colorectal cancer. It is able to 
detect bleeding and non-bleeding types, which a fecal occult blood test 
cannot do (Tonus, Sellinger, Koss, & Neupert, 2012). 
 
1.2. Cell Survival, proliferation and apoptosis 
 
1.2.1. Cell cycle progression 
 
Recently, research has been shifted towards finding targeted therapies 
for cancer. The molecular basis of cell survival, cell cycle, and cell death is 
nowadays the hot topic. The cell cycle in eukaryotes is divided to two main 
phases: interphase and mitosis (M). The first is divided into gap 1 phase (G1), 
DNA synthesis phase (S), and gap 2 phase (G2) (Maddika, et al., 2007). 
During the G1 phase, cells are diploid (2n). They produce proteins 
needed in later stages, and grow in size (Collins & Garrett, 2005). Next, cells 
enter the S phase, where DNA replication takes place. At this stage, cells 
double their DNA content and become 4n (Schafer, 1998). Then, cells enter 
the G2 phase. There, they undergo further cellular growth. At the end of this 
phase, cells become prepared for the M phase (Maddika, et al., 2007). During 
the M phase, most cells divide producing two identical diploid daughter cells. 
Others either stop dividing or are inactive by exiting the cell cycle and 
entering the G0 phase (Collins & Garrett, 2005; Maddika, et al., 2007). 
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At the end of each phase, checkpoints allow the activation and arrest 
of several repair mechanisms in cases of malfunction (Schafer, 1998). After 
the cell passes a checkpoint, it becomes irretrievably committed to continue 
through the subsequent phase (Park & Lee, 2003). Critical malfunctions such 
as DNA damage can lead to cell cycle arrest and trigger the apoptotic cascade 
pathway, resulting in programmed cell death. Hence, apoptosis is an 
important defence mechanism during the succession of cell cycle, which 
prevents the propagation of unwanted or damaged cells (Maddika, et al., 
2007; Park & Lee, 2003). 
In order to guarantee proper cellular growth and proliferation, 
regulated machinery control the cell cycle progression. One of the most 
important regulators is the family of Cyclin-dependant kinases or CDKs. 
These allow the smooth transition from a phase to another (Maddika, et al., 
2007). They are serine/threonine kinases, and are only activated at specific 
periods of the cell cycle (Collins & Garrett, 2005). When binding to their 
respective cyclins, CDKs are positively regulated, and then targeted to the 
nucleus whereby cell division is catalyzed (Park & Lee, 2003). At every 
phase of the cell cycle, different cyclins are produced. They all undergo a 
cyclic expression. Normally, cyclins are degraded at the end of each phase, 
and other new cyclins of the next phase are produced. As a result, the levels 
of different cyclins change according to the phase the cell is in. However, 
CDK levels remain constant (Schafer, 1998; Varmeulen, Van Bockstaele, & 
Berneman, 2003). 
 
1.2.2. PI3Kinase/Akt pathway controls cell survival  
 
One of the most important survival pathways is the 
Phosphatidylinositol 3-kinase (PI3-K) signaling pathway. When activated by 
countless stimuli, this pathway regulates essential cellular functions, 
including apoptosis, cell cycle progression, gene transcription, growth and 
proliferation (Maddika, et al., 2007; Vivanco & Sawyers, 2002). As their 
name indicates, these phosphatidylinositol kinases catalyze the 
phosphorylation of phosphoinositides. They are classified according to their 
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subunit organization and their substrate specificity (Dbouk & Backer, 2010; 
Engelman, Luo, & Cantley, 2006). 
PI3Ks are divided into two main classes: class IA and class IB. The 
first consists of heterodimer PI3Ks, with a p110 catalytic subunit and p50, 
p55, and p85 regulatory subunits. These are activated downstream of RTKs 
or receptor tyrosine kinases. The second class are dimers composed of a 
catalytic subunit p110 and regulatory subunits p87 and p101. PI3Ks of class 
IB are activated downstream of GPCRs or G-protein coupled receptors 
(Backer, 2008; Dbouk & Backer, 2010). Upon activation, PI3Ks will 
phosphorylate PI(4,5)P2, localized on the membrane, to produce PI(3,4,5)P3. 
In turn, this will create a docking site for many other downstream proteins 
with the PH or pleckstrin homology domain. All this will help activate 
various intracellular proteins that are involved in interconnected signaling 
pathways that regulate cell motility, proliferation, and survival (Figure 2) 
(Maddika, et al., 2007; Vivanco & Sawyers, 2002). 
 
Figure 2: Plasma membrane receptors and protein kinases. Both classes of 
PI3Ks, downstream from GPCRs and RTKs play important roles in many signalling 
pathways, eventually affecting gene and protein regulation. Source: (Kanoh & 
Rubin, 2010) 
 12 
 
One main downstream effector of PI3K is Akt. It controls cell survival 
by phosphorylating several substrates that are in turn involved in apoptotic 
and survival pathways. Its PH domain will help recruit it to the cell 
membrane, where it binds to PIP3. It is then phosphorylated and activated by 
mTOR and PDK1 kinases. The pro-apoptotic protein Bad, of the Bcl-2 
family, is a main target of Akt. So, after Akt is activated, it phosphorylates 
Bad. This will release the associated apoptosis inhibitory protein and blocks 
the apoptotic pathway. In parallel, Akt can also phosphorylate caspase-9. This 
will induce the caspase-9 to undergo a conformational change, resulting in the 
inhibition of its proteolytic activity, and also blocking apoptosis and 
promoting cell survival (Figure 3) (Maddika, et al., 2007; Vivanco & 
Sawyers, 2002). 
 
 
Figure 3: Akt promotes growth factor-related cell survival. Downstream from 
PI3K, activated Akt phosphorylates Bad, which dissociates form the inactive 
apoptosis-inhibitory protein. Bad will then lose its pro-apoptotic function, and 
apoptosis is inhibited. Source: (Ramaswamy, et al., 1999) 
 
1.2.3. Tumor suppressors and oncogenes  
 
Tumor suppressors are known as anti-oncogenes. They protect 
multicellular organisms from mutations randomly affecting many different 
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cellular functions, including cell differentiation and migration, mitogenic 
signaling, protein degradation and ubiquitination, cell cycle check point 
responses, DNA damage repair, and tumor angiogenesis (Sherr, 2004). Under 
normal conditions, tumor suppressors negatively regulate cellular 
proliferation. This is why the inactivation of these proteins allows the 
development of malignant phenotypes. This is supported by the fact that, in 
most human cancer cells, critical tumor suppressor genes are mutated (Viallet 
& Minna, 1990). 
Among the most important members of the tumor suppressor proteins, 
p53, mainly a transcription factor, has a significant role in the regulation of 
cellular responses to a range of stress signals. Thus, the end result will favour 
apoptosis, cell cycle arrest, or senescence (Levine, Momand, & Finlay, 1991). 
In response to DNA damage, p53 will enhance the transcription of genes that 
are involved in repair mechanisms, angiogenesis, apoptosis, and cellular 
growth. It can also have non-transcriptional activities that promote cell 
survival (Brown, Lain, Verma, Fersht, & Lane, 2009). In turn, if DNA repair 
is defected, tumor suppressors are inactivated, and thus might lead to cancer 
such as hereditary and sporadic colon cancers (Markowitz S. , 2000). 
Oncogenes are altered proto-oncogenes with acknowledged roles in 
the promotion of cellular transformation and initiations of neoplastic growth. 
Mutations resulting in the constitutive activation of these proteins lead to 
cellular transformation and alteration (Viallet & Minna, 1990). One system 
for classifying oncogenes is dividing them into five main categories: growth 
factors, tyrosine kinases (receptor and cytoplasmic), serine/threonine kinases, 
GTPases, and transcription factors (Croce, 2008). As we can notice, they 
were grouped according to their function and location in the cell, meaning 
that these two criteria interrelate. For example, proteins in the inner cell 
membrane are involved in signal transduction, such as Ras. Other 
oncoproteins c-myc and c-jun are involved in transcription and cell cycle 
regulation. These are nuclear proteins (Evans, 1993; Maddika, et al., 2007). 
Since oncoproteins are located in various sites of the cell and accordingly 
undergo different functions, this implicates their joint role in exceeding 
growth, eventually leading to unrestrained cell proliferation and finally 
carcinogenesis (Figure 4) (Harrington, Fanidi, & Evan, 1994). 
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Figure 4: MAPK signaling in pathogenesis. Downstream effectors of the Ras 
pathway are key elements in cellular processes such as angiogenesis, proliferation, 
apoptosis, differentiation, and metastases. Source: (Fang & Richardson, 2005) 
 
For the above mentioned reasons, tumor suppressors and oncogenes 
have antagonistic relationships in most cancer systems. This is illustrated by 
the inactivation of the first and the constitutive activation of the second 
(Viallet & Minna, 1990). 
 
1.2.4. Apoptotic pathways 
 
Apoptosis is termed programmed cell death. It results in 
morphological changes of cells and death. It plays important roles in 
embryogenesis, immunology, etc. Quite a number of complex signaling 
pathways are involved in apoptotic regulation, two of which are the intrinsic 
pathway or p53-mitochondrial pathway, and the extrinsic pathway activated 
by the binding of external ligands to specific membrane receptors called death 
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receptors (Muñoz-Pinedo, 2012; Taylor, Cullen, & Martine, 2008). In 
colorectal cancer, survivin is mostly responsible for apoptotic inhibition 
(Kawasaki, et al., 1998). The intrinsic pathway is mainly regulated by the Bcl 
family of proteins. They include pro-apoptotic Bax and Bad proteins, and 
anti-apoptotic Bcl-2 protein. 
As compared to normal conditions, Bcl-2 is highly expressed in 
colorectal cancer patients. This phenomenon is also associated with the 
overexpression of several hormone receptors (Giannoulis, et al., 2004; 
Poinclous, et al., 2009). This is all significant, since Bcl-2 regulates the 
permeability of the mitochondrial membrane, thus indirectly restraining 
apoptosis. It inhibits secretory pore formation; through which cytochrome c 
exit the mitochondria. Subsequently, the apoptotic pathway would be 
incomplete due to the inhibition of caspase assembly (Ruvolo, Deng, & May, 
2001; Srivastava, et al., 1998). 
On the other hand, the pro-apoptotic proteins Bax and Bad are 
accountable for the formation of these pores in the mitochondrial membrane, 
allowing the release of cytochrome c into the cytoplasm. This will then 
activate the assembly of caspase-3 and caspase-9. The proteolytic cleavage of 
PARP, a downstream protein, takes place, thus triggering apoptosis (Muñoz-
Pinedo, 2012). Both pro-apoptotic proteins are found to be down-regulated in 
patients with colorectal cancer, as compared to normal people (Jansson & 
Sun, 2002). 
It is important to note that the levels of both pro and anti-apoptotic 
proteins of the Bcl family decrease significantly as the colorectal cancer 
tumor increases in size and further metastasizes (Giannoulis, et al., 2004; 
Jansson & Sun, 2002; Poinclous, et al., 2009; Yokota, 2000). 
 
1.2.5. Altered cell growth and cancer 
 
Typically, disturbing the homeostatic regulation of signaling pathways 
will definitely result in altered cell growth and eventually promoting 
carcinogenesis. Mutations and changes within these very critical processes 
affect a major cascade of pathways leading to uncontrolled proliferation, 
prolonged cell survival, and reduced cell death (Maddika, et al., 2007). 
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The disruption of apoptotic regulation prolongs cell life, promoting 
cancer. In cancer cells, apoptosis is inhibited by anti-apoptotic proteins. This 
is also achieved by upsetting the homeostasis between oncogenes and tumor 
suppressors. All this will result in prominent cancer cell characteristics, i.e. 
prolonged survival and prevention of cell death (Maddika, et al., 2007). 
Along with inhibiting apoptotic pathways, mutations also result in the 
constitutive activation of survival pathways. Two of the most frequently 
disrupted survival pathways in humans cancers are the PI3-K/Akt and 
Ras/MAPK pathways. These mutations will also play major roles in tumor 
development and cell transformation, and most importantly in resistance to 
cancer treatments (Vivanco & Sawyers, 2002). 
Since it is a tightly regulated and highly organized process, changes in 
the programmed regulation of the cell cycle succession might result in cancer 
development and growth (Collins & Garrett, 2005; Park & Lee, 2003). Being 
greatly involved in mitogenic signal transduction, tumor suppressor genes are 
“turned off” and oncogenes are “turned on” in transformed cancerous cells. 
Hence, the deregulation of proteins such as p53, p21, pRb, mdm2, and many 
others, promotes uncontrolled growth and development of tumors (Schafer, 
1998). 
 
1.3. Cell Motility 
 
1.3.1. Cell motility cycle 
 
Numerous physiological events, such as embryogenesis, tissue 
regeneration, inflammation, and wound healing, greatly depend on cellular 
motility. But also, cellular motility is crucial for cancer cell invasion and 
metastasis. It occurs usually as a response to growth factors or 
chemoattractants found in the ECM, around the cell. This process is known as 
chemotaxis (Lauffenburger & Horwitz, 1996). Due to its major role, cell 
motility has been a highly researched phenomenon. Scientists have been 
directing their studies towards understanding its molecular basis, as this 
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might lead to novel targeted therapeutic treatments inhibiting tumor growth, 
development, and metastasis (El Zouhairi, Charabaty, & Pishvaian, 2011). 
Cell motility occurs in an amoeboid-like manner, after a signal is 
detected. It begins by determining the direction of motion, which is of course 
towards the chemoattractant. A protrusion is then extended from the cell 
towards the direction of motion. This is done by the polymerization of new 
actin filaments (Bailly, Condeelis, & Segall, 1998). The actin-rich protrusion 
is then stabilized by the adhesions formed to the cell substratum, providing 
anchorage to the cell. This will help transmit mechanical force, for the cell to 
pull its body forward and to the direction of motion. Concurrently, adhesion 
structures found at the rear edge of the cell will undergo disassembly, 
inducing the cell tail to retract moving the whole cell forward 
(Ananthakrishnan & Ehrlicher, 2007; Bailly, Yan, Whitesides, Condeelis, & 
Segall, 1998; Condeelis, et al., 2001). The family of Rho GTPases, including 
all its members, play a main role in regulating the cycle of cell motility, 
through the reorganization of the actin cytoskeleton (Condeelis J. S., 2001). 
 
 
Figure 5: The cell motility cycle. First, signal-induced actin polymerization defines 
cell direction. Then, protrusions are extended, after which they become stabilized by 
adhesion. At the rear end, old adhesions detach, and the tail retracts and the cell body 
is pulled forward. Source: (Childs, 2001) 
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1.3.2. Altered cell motility and cancer 
 
Cell motility is an intricate multistep process, integrating numerous 
regulatory and signaling pathways. Any slight deviation or malfunction at any 
step of the pathway may radically affect normal functions, resulting in 
transformation and carcinogenesis (Lauffenburger & Horwitz, 1996). 
Acquiring a motile phenotype is an important characteristic of 
cancerous cells. It is a critical step towards gaining metastatic competence. 
Thus, targeting cell motility processes will help in introducing novel 
therapeutic agents against metastatic and invasive tumors (Silva, 2004). 
 
1.4. Cell Invasion 
 
During metastasis, tumor cells migrate from the primary site to secondary 
sites. They must first degrade the basement membrane, penetrate the extracellular 
matrix (ECM), and then migrate towards the lymph and blood (Figure 6) (Gertler & 
Condeelis, 2011; Kim, Liotta, & Kohn, 1993; Sahai, 2005). 
 
 
Figure 6: Process of invasion and metastasis. Cells first grow as benign tumors, 
invade through the basement membrane into the blood stream, where they travel, and 
adhere to a capillary wall. They will then extravasate and proliferate to form 
metastases. Source: (Alberts, et al., 2002). 
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Cell invasion is referred to as the shift from primary benign tumors to 
malignant-acquired phenotypes. This involves the coordination and organization of 
both extracellular and intracellular communications (Calvo & Sahai, 2011). 
 
1.4.1. ECM degradation 
 
At first, the ECM must be successfully degraded at the site where 
cancer cells transverse the underlying basement membrane and invade to the 
interstitial stroma. Components of the ECM, such as proteoglycans, 
glycoproteins, and collagen type IV, must be effectively proteolysed (Kim, 
Liotta, & Kohn, 1993). Cancer cells would either secrete proteases or factors 
activating matrix proteases, such as matrix metalloproteinases (MMPs), 
which are associated with poor prognosis in colorectal cancer (Murray, 
Duncan, O'Neil, Melvin, & Fothergrill, 1996). These are secreted in their 
inactive pro-enzyme form, and are activated extracellularly by the help of 
plasmin. For this to successfully happen, MMPs must evade endogenous 
inhibitors, such as TIMPs. Therefore, there must be a homeostatic balance 
among active proteases and their inhibitors. This will determine the exact 
invasive phenotype of the tumor cells (Aznavoorian, Murphy, Stetler-
Stevenson, & Liotta, 1993; Gertler & Condeelis, 2011; Stetler-Stevenson, 
Aznavoorian, & Liotta, 1993). 
After successfully degrading the ECM, cells can now reach the 
circulatory system, by the help of a process called angiogenesis. This will 
facilitate the tumor in expanding and gaining easier access to vascular tissues 
(Aznavoorian, Murphy, Stetler-Stevenson, & Liotta, 1993). Continuously, 
components of the tumor environment will interact with the surrounding host 
tissue of the secondary site (Calvo & Sahai, 2011). This is done through a 
complex network of interconnected molecular pathways that highly influence 
cell migration (Brabletz, et al., 2005). Eventually, circulating cancer cells still 
have to escape the host immune system, extravasate, invade, and proliferate 
in the secondary site. Thus, neoplastic tissues will then be effectively 
established at distant sites (Gertler & Condeelis, 2011; Kim, Liotta, & Kohn, 
1993; Brabletz, et al., 2005). 
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1.4.2. Molecular mechanism of invasion 
 
During invasion, tumor cells must form membrane protrusions rich in 
F-actin. These are known as invadopodia. With the help of matrix 
metalloproteinases, successive steps during invasion would be accomplished 
by first degrading the dense barriers (Bravo-Cordero, et al., 2011). 
Invadopodia vertically extend into the ECM. They are enriched in actin 
filaments, regulatory and binding proteins, and matrix proteinases (Condeelis 
& Segall, 2003; Yamaguchi, et al., 2005). 
The molecular mechanisms involved in invasion mainly regulate 
invadopodia dynamics and induce signaling pathways. These pathways 
comprise of various proteins, such as N-WASP, cortactin, Arp2/3, cofilin, 
and MT1-MMP (Artym, Zhang, Seillier-Moiseiwitsch, Yamada, & Mueller, 
2006; Yamaguchi, et al., 2005). 
Cofilin is a very important signaling protein. It generates free barbed 
ends after cutting actin filaments, leading to the nucleation of actin. Severing 
is crucial. It exposes the filaments, since most of them are covered and 
capped in resting cells. Cofilin is inactivated by TES and LIM families. These 
kinases phosphorylate and block cofilin’s binding to F-actin (Bravo-Cordero, 
et al., 2011). It has been previously proven that the Rho family of small 
GTPases activate ROCK, a downstream kinase, which in turn activates the 
LIM kinase (LIMK) by phosphorylating it (Olson & Sahai, 2009). 
Other than severing of actin filaments, barbed ends can be generated 
by a process called de novo nucleation. It is mediated by Arp2/3 complex, 
providing a template for actin nucleation (Olson & Sahai, 2009). The Arp2/3 
complex is activated by the WASP family of proteins, Wiskott-Aldrich 
syndrome protein. Several scaffold proteins, WASP/SCAR/WAVE, have a 
VCA domain, through which they can directly bind to Arp2/3. All these 
proteins are key regulators for actin polymerization (Olson & Sahai, 2009; 
Yamaguchi, et al., 2005). 
In all, the activation, inhibition, and regulation of the dynamics of 
actin, especially in invadopodia, are essential for the invasion and metastasis 
of tumors. 
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1.4.3. EMT 
 
A very prominent fact is that tumor progression is mainly based on 
epithelial-mesenchymal transition (EMT). It is also well known that the EMT 
process is accountable for the spreading and propagation of primary 
cancerous cells to secondary metastatic sites (Thierry, 2002). 
A series of events must take place accordingly for the EMT of cancer 
to progress. Epithelial markers must be downregulated, while mesenchymal 
proteins must be upregulated. Morphologically, this is portrayed by increased 
motility, loss of cell-cell adhesion, pseudopodia formation, and elongated 
polarized shapes (Morra & Moch, 2011; Thierry, 2002). 
EMT favours the progression and stability of metastasized tumors, by 
overcoming safeguard mechanisms and attenuating the immune system. This 
is accomplished by overcoming apoptotic pathways and premature 
senescence (Nieto, 2011). In addition, EMT helps in acquiring resistance 
against radiotherapy and chemotherapy. However, in order for secondary site 
tumors to stabilize and colonize, they must revert back to their epithelial 
nature, a process known as MET (Nieto, 2011; Thierry, 2002). 
 
 
1.5. Rho family GTPases 
 
The family of Rho GTPases consists of small GTP-binding proteins, ranging 
between 20 and 40 KDa. They are key members in cancer cell motility and invasion. 
They play important roles in signal transduction, cytoskeleton re-organization, and 
cellular polarity (Boettner & Van Aelst, 2002). The gravity of their role lies in the 
fact that a simple biochemical idea is behind these biological complexities. By 
switching on only one single GTPase, a number of pathways will be activated co-
ordinately. Thus, the harmonization of spatial and temporal switching of several 
GTPases is what makes this family prominent in eukaryotic cell biology (Etienne-
Manneville & Hall, 2002). The three most considered Rho GTPases are Rho, Rac 
and Cdc42. They have distinct functions than other members of their family (Takai, 
Sasaki, & Matozaki, 2001; Vega & Ridley, 2008). 
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1.5.1. General structure of Rho GTPases 
 
Figure 7: Primary structure of Rho GTPases. Source: (Gad & Aspenström, 2010) 
 
All members of the Rho GTPase family have a constant sequence of 
amino acids at their N-terminal where they bind to GDP and GTP, acquiring 
their GTPases activity to hydrolyze them (Johnson, 1999; Valencia, Chardin, 
Wittinghofer, & Sander, 1991). An important Rho binding domain is Switch 
I, responsible for downstream effectors (Marshall, 1993). At their C-terminal, 
the CAAX box undergoes post-translational changes important for their 
proper localization in the cell (Magee, et al., 1992) (Figure 7). 
 
1.5.2. Rho GTPases as binary switches 
The tight control over the activity of Rho GTPases is based on their 
subcellular localization and nucleotide binding (Wennerberg & Der, 2004). 
Thus, they switch between an inactive form when bound to GDP and 
localized in the cytoplasm, and an active form when bound to GTP and 
recruited to the plasma membrane (Vega & Ridley, 2008) (Figure 8). 
 
 
Figure 8: The Regulation of Rho family of proteins. GDI: guanine nucleotide 
dissociation inhibitor, GEF: guanine nucleotide exchange factor, and GAP: GTPase 
activating protein. Source: (Raftopoulou & Hall, 2004). 
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Certain upstream signals will activate the Rho GTPases, by 
phosphorylating its GDP to GTP, inducing a conformational change that 
favours downstream effectors to bind to Rho GTPases. Then, GTP is 
hydrolyzed back to GDP and the GTPase returns back to its inactive form, 
completing one cycle of GTPases activation and inactivation (Etienne-
Manneville & Hall, 2002; Jaffe & Hall, 2005). 
 
 
1.5.3. Rho GTPases and their regulation 
As shown in figure 8, the regulation of a Rho protein and its switch 
from the inactive to the active form is done by GEFs, GAPs, and GDIs. 
 
 
1.5.3.1. GEFs 
 
The primary dissociation of GDP from inactive Rho GTPases is 
known to be the rate-limiting step. It is a very slow reaction that must be 
stimulated by GEFs. They have several important domains, such as the 
pleckstrin homology domain (PH), Src homology 3 domain (SH3), and 
Dbl homology domain (DH). GEFs alter the GDP-GTP exchange, by 
interacting with phospholipids of proteins at the cell membrane. 
Therefore, GEFs activate Rho GTPases (Grise, Bidaud, & Moreau, 2009; 
Schmidt & Hall, 2002). 
 
 
1.5.3.2. GAPs 
 
As their name indicates, GAPs are proteins that activate the 
intrinsic GTPase activity of Rho GTPases. This will hydrolyze the GTP 
into GDP, thus transforming Rho GTPases back to their inactive form. 
Also, GAPs may mediate other downstream functions of Rho GTPases 
(Grise, Bidaud, & Moreau, 2009). Hence, GAPs negatively regulate Rho 
GTPases, rendering them inactive (Moon & Zheng, 2003). 
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1.5.3.3. GDIs 
 
GDIs play a very important role. They inhibit GEFs and GAPs. 
They prevent the GDP dissociation of inactive Rho GTPases, and the 
interaction of active forms with GAPs. Continuously, they aid in the 
cycling of Rho GTPases between the cell membrane and the cytoplasm. 
In the cytoplasm, GDIs mask the binding domains of GTPases, thus 
sequestering them away from the cell membrane, which is the site of 
their activation. This is crucial, since temporal and spatial properties are 
key characteristics for the regulation of Rho GTPases (DerMardirossian 
& Bokoch, 2005; Garcia-Mata, Boulter, & Burridge, 2011; Grise, 
Bidaud, & Moreau, 2009). 
 
1.6. Signaling pathways of Rho GTPases 
 
Many plasma membrane receptors capture extracellular stimuli and activate 
the Rho family of GTPases. Growth factors and mitogens are upstream signals 
regulating Rho GTPases, which activate downstream effectors (Figure 8). In turn, 
these proteins translate the signals, regulating countless functions like chemotaxis, 
polarity, cell adhesion, proliferation, cell-cell interaction, cytoskeleton re-
organization, etc (Sahai & Marshall, 2002). 
 
1.6.1. Upstream signaling 
 
1.6.1.1. PI3K signaling 
 
GEFs have a PH domain with high affinity to phosphoinositides, 
such as PI(4,5)P2 found on the plasma membrane (Macias, et al., 1994). 
PI(4,5)P2 binds to GEF, favouring the interaction between PH and DH 
domains of GEF. It is then phosphorylated by PI3K forming PI(3,4,5)P3, 
inducing its binding to the PH domain. This leads to the dissociation of 
DH catalytic domain, which in turn will activate the GEF. Consecutively, 
GEF will bind and activate Rho GTPases (Schmidt & Hall, 2002). 
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Several studies have shown that PI3K works upstream of Rho 
GTPases. Insulin, EGF, PDGF, and LPA are external signals triggering 
the activation of Rho GTPases through the PI3K pathway. This was 
shown by treating fibroblasts with wortmannin, which is a PI3K 
inhibitor. Rho and Rac, members of the Rho GTPase family, were 
inhibited, suggesting that in response to growth factors, GTPases are 
downstream of PI3K (Nobes, Hawkins, Stephens, & Hall, 1995). 
A renowned GEF, also activated by PI3K, is Vav. It is activated 
by Src kinases, which in turn activates its catalytic domain (Lopez-Lago, 
Lee, Cruz, Movilla, & Bustelo, 2000). This is achieved when Vav binds 
PI(3,4,5)P3, thus weakening the PH/DH interaction. The auto-inhibition 
exerted by the PH domain is alleviated (Bustelo, 2000; Crespo, Schuebel, 
Ostrom, Gutkind, & Bustelo, 1997). 
Another important GEF is Son of sevenless (Sos). It binds to PIP3 
through its PH domain, removing auto-inhibition. Downstream of 
receptor tyrosine kinases (RTKs), Sos binds many adaptor proteins (Das, 
et al., 2000). 
The subcellular localization of GEFs is important for Rho GTPase 
activation. This spatial regulation is achieved by active PI3K producing 
PIP3, rendering the loss of the PH domain. Another motif targeting the 
protein to the plasma membrane is CAAX (Etienne-Manneville & Hall, 
2002). 
Conducted research has shown that Rho GTPases and PI3K are 
highly involved in cancer cell motility, by stimulating lamellipodia 
formation. This is further proved by showing that Rac and Cdc42 are 
upstream of PI3K (Keely, Westwick, Whitehead, Der, & Parise, 1997). 
 
1.6.1.2. Activation by adhesion 
 
Other than upstream signals, cell-ECM adhesion also stimulates 
Rho GTPase activation. Focal adhesion kinases (FAKs) are activated, 
leading to paxillin and p130cas phosphorylation and activation (DeMali 
& Burridge, 2003; Zamir & Geiger, 2001). 
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Upon phosphorylation, p130cas forms complexes with Crk and 
DOCK180, a GEF for Rac (Cary, Han, Polte, Hanks, & Guan, 1998; 
Klemke, et al., 1998; Matsuda, et al., 1996). Also, when phosphorylated, 
paxillin complexes with PKL and PIX, another GEF for Rac (Bagrodias, 
Taylor, Jordan, Van Aelst, & Cerione, 1998). 
Other than activating Rac, FAK inhibits RhoA by activating 
p190RhoGAP. This is why in most cells low RhoA activity but high Rac 
activity are stimulated by FAK activation (O'Connor, Nguyen, & 
Mercurio, 2000). 
 
1.6.2. Downstream signaling 
 
Major downstream effectors of the PI3K signaling pathway are small 
GTPases, such as Rho, Rac, and Cdc42. These are important regulators of the 
cell cytoskeleton, by promoting actomyosin assembly, stress fiber formation, 
actin nucleation and polymerization, etc (Ananthakrishnan & Ehrlicher, 2007; 
Etienne-Manneville & Hall, 2002; Zhou & Sinder, 2006). 
 
 
Figure 9: Downstream effectors of Rho, Rac, and Cdc42. Explained in sections 
1.6.2.1 and 1.6.2.2. Red arrows indicate inhibition, while green arrows indicate 
activation. Source: (Zhou & Sinder, 2006). 
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1.6.2.1. Rho Effectors 
 
Rho is known to be indirectly regulated by the PI3K pathway. 
One of its main effectors is p160ROCK, the serine/threonine kinase 
involved in focal adhesions and stress fibers formation. Through ROCK, 
the myosin light chain (MLC) is phosphorylated, and actin dynamics are 
regulated by the contractility of actin and myosin (Figure 9) (Grise, 
Bidaud, & Moreau, 2009; Kimura, et al., 1996; Struckhoff, Rana, & 
Worthylake, 2011). Also, studies have shown that Rho can inactivate 
GSK-3 through mammalian homolog of diaphanous (mDia) activation, 
leading to actin nucleation and stress fiber formation (Alberts A. S., 
2001). 
Another downstream protein is LIMK. It phosphorylates cofilin, 
rendering it inactive as mentioned previously. Cofilin is known to be a 
protein that severs actin (Olson & Sahai, 2009). 
Members of the ERM family of proteins, known as ezrin-radixin-
meosin proteins, are Rho effectors. They are associated with the plasma 
membrane, where active Rho is translocated, and actin cytoskeleton 
remodelling take place (Takaishi, Sasaki, Kameyama, Tsukita, & Takai, 
1995). 
 
1.6.2.2. Rac/Cdc42 Effectors 
 
The VCA is a consensus domain found in all downstream 
effectors of Rac and Cdc42. It is found in the WASP/SCAR/WAVE 
family of proteins (Keely, Westwick, Whitehead, Der, & Parise, 1997). 
PAK is a serine/threonine p21 activating kinase. It is an effector 
of Rac and Cdc42. These proteins have a catalytic domain at their C-
terminal, and a regulatory domain at their N-terminal (Manser, Leung, 
Salihuddin, Zhao, & Lim, 1994). They also have a common domain 
where Rac and Cdc bind, called the CRIB domain, or the Cdc42/Rac 
interactive binding domain (Burbelo & Drechsel, 1995). When active 
GTPases bind to PAK, the regulatory domain is disrupted and the 
catalytic domain is activated by phosphorylation, rendering PAK active 
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(Manser, Leung, Salihuddin, Zhao, & Lim, 1994). Active PAK has a 
couple of important roles. It inactivates MLCK by phosphorylating it, 
consecutively activating MLC by inhibiting its phosphorylation (Sanders, 
Matsumura, Bokoch, & de Lanerolle, 1999). Another role is to 
phosphorylate and activate LIMK, when targeted to adhesion complexes 
(Figure 9) (Bokoch, 2003; Burridge & Wennerberg, 2004; Edwards, 
Sanders, Bokoch, & Gill, 1999). 
 
1.7. Role of Rho GTPases in 2D and 3D cell migration 
 
 
Figure 10: Rho GTPases in cell motility. A: 2D cell motility. B: 3D cell motility. 
 
Cell motility cycle involves several consecutive steps, including: direction of 
motion, cell polarization, formation of protrusions, adhesion, cell body contraction, 
and retraction of the tail (Lauffenburger & Horwitz, 1996). 
 
1.7.1. Direction of motion and protrusion formation 
 
The determination of the direction of motion is the initial step in the 
motility cycle. Membrane protrusions are generated and can be either 
lamellipodia or filopodia. 
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At the cell edge, a lamellipodium is a meshwork of actin filaments 
(Small, Stradal, & Rottner, 2002). It involves effectors downstream to Rac, 
such as the Arp2/3 complex, ADF/cofilin (Van Troys, et al., 2008), and PIP-
5-K activation. Thus, these lamellipodia are Rac-dependent. Yet, these are 
also downstream of Cdc42. Thus, Cdc42 is known to be a possible regulator, 
driving Rac-dependent lamellipodia (El-Sibai, et al., 2007; Hall, 1998). 
Another form of protrusions is the filopodia, which functions as a 
sensor for chemoattractants during migration. They pull out from the cell to 
detect any environmental alterations (Arjonen, Kaukonen, & Ivaska, 2011; 
Ridley, 2001). By activating N-WASP, actin polymerization occurs, leading 
to the formation of filopodia. This is regulated by Cdc42 (Nobes & Hall, 
1999). 
In addition, Cdc42 regulates cell polarity and direction of motion 
through the microtubule cytoskeleton (Johnson, 1999). 
 
1.7.2. Adhesion formation 
 
After the formation of protrusions, these must stabilize and adhere to 
the ECM, thus activating Rac and Cdc42 required for cell spreading 
(Condeelis J. S., 2001; Price, Leng, Schwartz, & Bokoch, 1998). Relative 
levels of active Rho GTPases, i.e. Rho, Rac, and Cdc42, is an indication of 
the composition of the substratum, which in turn signifies the speed of cell 
migration. Hence, the interaction between Rac and integrins is crucial for the 
cell to respond with respect to the changing substratum composition (Nobes 
& Hall, 1999; Price, Leng, Schwartz, & Bokoch, 1998; Ridley, 2001). 
The interplay between Rac and RhoA defines adhesion formation of 
cell (Rottner, Hall, & Small, 1999). The former is responsible for the 
formation of primary focal complexes by activating PAK, which 
consecutively interact with PIX, paxillin, and GIT proteins. Another pathway 
for the formation of these focal complexes behind the lamellipodia is to 
antagonize Rho activation (Sander, ten Klooster, van Delft, van der Kammen, 
& Collard, 1999). These complexes are not enough to transmit contractility 
during cell movement (Kaverina, Krylyshkina, & Small, 2002). Therefore, 
focal complexes will mature into more stabilized Rho-dependent focal 
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adhesions (Arjonen, Kaukonen, & Ivaska, 2011; Wolfenson, Henis, Geiger, 
& Bershadsky, 2009). These will confer anchorage and strength for the cell 
body to contract and the cell to slide and move forward along the ECM 
(Wolfenson, Henis, Geiger, & Bershadsky, 2009). Increased RhoA activation 
will further stabilize focal adhesions, consequently inhibiting cell movement 
(Cox, Sastry, & Huttenlocher, 2001). 
 
1.7.3. Cell body contraction and tail retraction 
 
After adhesion is acquired, contraction of the cell body and then 
retraction of the tail are needed (Figure 5). 
The first process depends on actomyosin contractility, regulated by 
Rho. As observed in figure 9, downstream from Rho and upon activation, 
ROCK induces contractility by phosphorylating MLC. So, sites of adhesion 
become tense and contractile. Other than the Rho/ROCK pathway, MLC is 
regulated by MLCK (Sanders, Matsumura, Bokoch, & de Lanerolle, 1999). 
Other than the ROCK pathway, cell protrusions are inhibited by RhoA, which 
inactivates cofilin (El-Sibai, et al., 2008; Worthylake & Burridge, 2003). 
Hence, RhoA is localized to the leading edge to activate ROCK, transmitting 
tension to the sites of adhesion, and to the rear end to inactivate cofilin and 
inhibit protrusions. 
The final process of cell motility is tail retraction, i.e. adhesions at the 
rear end must disassemble (Palecek, Huttenlocher, Horwitz, & Lauffenburger, 
1998). Reduced RhoA activity inhibits retraction by decreasing actomyosin 
contractility (Cox, Sastry, & Huttenlocher, 2001; El-Sibai, et al., 2008; 
Worthylake & Burridge, 2003). 
 
1.7.4. Crosstalk between Rho GTPases 
 
Primary research has shown that each of the different proteins in the 
family of Rho GTPases has a well-defined unique role in actin regulation and 
adhesion dynamics during cell migration. Nevertheless, recent research has 
proved the presence of a prominent crosstalk among all signalling pathways 
of Rho, Rac, and Cdc42 (Khalil & El-Sibai, 2012). For instance, Rho and Rac 
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have antagonistic relationships, where the activation of one leads to the 
inactivation of the other. This is mainly done through stimulating either a 
GAP or a GEF (Burridge & Wennerberg, 2004; Sander, ten Klooster, van 
Delft, van der Kammen, & Collard, 1999). Another example is the crosstalk 
of RhoA with Rac and Cdc42 at the rear end of the cell, which aids in the 
regulation of the actin cytoskeleton (El-Sibai, et al., 2008). 
 
1.7.5. Altered role in cancer 
 
One of the most important characteristics a cancer can acquire is the 
ability to move, invade, and metastasize. These processes are tightly regulated 
by Rho GTPases. Genetic screening studies have conveyed that RhoA and 
RhoC, two members of the Rho GTPase family, are hyperactive and over 
expressed in colorectal cancer cells, as well as many other types of tumors 
(Sahai & Marshall, 2002). Furthermore, the inactivity or the expression of the 
negatively dominant form of Rho led to the inhibition of motility (Clark, 
Golub, Lander, & Hynes, 2000). 
Mostly important proteins, GAPs and GEFs, have major roles in the 
dominant inhibition or activation of Rho GTPases. This in turn affects 
motility, invasion, and metastasis of colorectal cancer cells (Brabletz, et al., 
2005; Jaffe & Hall, 2005). Furthermore, it is not necessary for the 
dysfunction to occur at the level of Rho GTPases only. Any inhibition in the 
downstream effectors in these pathways will lead to malfunctions in the 
processes. For instance, inhibiting RhoA by C3T, or inhibiting ROCK by 
Y27632 will result in less motility, and inhibited maturation of focal 
complexes into adhesion (El-Sibai, et al., 2008). 
Prolonged survival and apoptotic inhibition are both side effects of 
abnormal Rho activation. This is possible through the pathway involving 
CDKs, which highly regulate progression of the cell cycle and support tumor 
growth (Tatsuno, Hirai, & Saito, 2000). In most cancers, CD-1 is highly over 
expressed. This is correlated to the activation of Rho GTPases and 
transcription factors, such as ATF-2 and NF-κB. These factors activate CD-1 
promoter through direct binding (Guttridge, Albanese, Reuther, Pestell, & 
Baldwin, 1999). The main Rho GTPase involved is Rac1. When dominantly 
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active, it stimulates proliferation and transformation through over expressing 
CD-1. Also, the inhibition of CDK inhibitors, such as p21 which is also a 
tumor suppressor, is mediated through over expressing a member of the 
RhoGTPase family, RhoA (Joyce, et al., 1999). 
This is why massive research is conducted to use targeted therapies 
for cancer, especially towards RhoGTPases, such as strongylophorine-26 
(McHardy, Warabi, Anderson, Roskelley, & Roberge, 2005) and FTI drugs, 
or targeting downstream effectors, such as Y-27632 ROCK inhibitor (Du & 
Prendergast, 1999). 
 
1.8. StarD13 
 
StarD13, or START-GAP2, is also known as the DLC2 gene. It was first 
identified by Ching et al. (2003) to be downregulated in hepatocellular carcinoma. It 
is located on position 13q12.3 (Popescu & Durkin, 2004). StarD13, or steriodogenic 
acute regulatory protein-related lipid transfer domain-containing protein 13, has a C-
terminal START domain and an N-terminal SAM domain. In between, it holds a 
GAP domain for Rho GTPases. It has four known isoforms: α, β, γ, and δ (Figure 11) 
(Ching, et al., 2003; Thorsell, et al., 2011; Ullmannova & Popescu, 2006). 
 
 
Figure 11: StarD13 structural domains. A: It has N-terminal SAM domain, an 
ATP/GTP-binding domain, a GAP domain and a C-terminal START domain. B: 
DLC-2 isomers and their structural domains. Source: (Thorsell, et al., 2011). 
 
1.8.1. Role as a tumor suppressor 
 
StarD13 is a member of the DLC (deleted in liver cancer) family, 
which is known to be a family of tumor suppressors. It has 64% homology 
with DLC-1 (Durkin, et al., 2007; Ullmannova & Popescu, 2006). Research 
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conducted on DLC-1 has shown that it is underexpressed in many types of 
cancer, such as stomach, uterus, breast, colon, kidney, prostate, and lung 
(Liao & Lo, 2008). Also, DLC-2 was found to be overexpressed in cells of 
low rates of growth and proliferation (Ching, et al., 2003). All the above 
suggest a prominent role of StarD13 as a tumor suppressor (El-Sitt, et al., 
2012). 
 
1.8.2. StarD13 activity and localization 
 
Studies showed that StarD13 inhibits Cdc42 and RhoA, which in turn 
inhibits the formation of actin stress fibers (Ching, et al., 2003). Furthermore, 
StarD13 is targeted towards the mitochondria through its START domain. 
This demonstrates its potential role in regulating the permeability of the 
mitochondrial membranes, activating pathways of apoptosis (Ng, et al., 
2006). Another domain that targets StarD13 to focal adhesions is the N-
terminal FAT domain, which interacts with a constituent of focal adhesions 
named tensin2 (Kawai, et al., 2009). 
Moreover, research proved the RhoGAP activity of StarD13 on RhoA, 
i.e. RhoA is inhibited by StarD13. This is through the inhibition of actin 
stress fibers assembly, mediated by RhoA. Successively, and through this 
Rho-mediated pathway, cell transformation is inhibited, as well as the 
modulation of cell attachment, cell migration, and cell differentiation (Leung, 
et al., 2005; Lin, et al., 2010; Xiaorong, Wei, Liyuan, & Kaiyan, 2008). 
 
1.9. Purpose of the study 
 
Throughout this study, our aim was to investigate the role of StarD13 on the 
proliferation and motility of colorectal cancer cell lines. First, we studied its effect on 
cellular proliferation and viability upon knocking down and over expressing 
StarD13. Then, we examined its RhoGAP activity as well as its possible interaction 
with Rac1 and Cdc42, and their effect on the migration, invasion, and adhesion of 
colon cancer cells. The experiments include Trypan Blue Exclusion method, MTT, 
WST proliferation kits, wound healing assay, immunostaining, invasion, adhesion... 
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Chapter II 
MATERIALS & METHODS 
 
2.1. Cell culture 
 
Human colorectal cancer cell lines (Caco-2 and HT-29) obtained from ATCC, 
were cultured in Dulbecco’s Modified Eagle Medium, DMEM, (Sigma-Aldrich) 
supplemented with 10% Fetal Bovine Serum, FBS, (Sigma-Aldrich) and 100U or 1% 
(v/v) penicillin/streptomycin (Sigma-Aldrich) in a humidified chamber at 37°C and 
5% CO2. Cells were cultured in T-75 flasks (Corning). 
 
2.2. Antibodies and reagents 
 
Goat polyclonal anti-StarD13 antibody was obtained from Santa Cruz 
Biotechnology. Rabbit monoclonal anti-RhoA, mouse monoclonal anti-Rac1, mouse 
monoclonal anti-Cdc42 and mouse monoclonal anti-vinculin antibodies were 
purchased from Upstate Biotechnology, Lake Placid, NY. Anti-goat, anti-rabbit and 
anti-mouse HRP-conjugated secondary antibodies were obtained from Promega. 
Fluorescent secondary antibodies (AlexaFluor 488) were obtained from Invitrogen. To 
visualize the actin cytoskeleton, cells were stained with Rhodamine phalloidin 
(Invitrogen). 
 
2.3. Cell transfection with siRNA 
 
Goat FlexiTube siRNA (5nmol) for StarD13, RhoA, Rac1 and Cdc42 were 
obtained from Qiagen. Consecutively, their target sequences are: 
Hs_StarD13_3: 5’-CCCGCAATACGCTCAGTTATA-3’, 
Hs_StarD13_8: 5’-ATGGCTACATCCCTACTAATA-3’, 
Hs_RhoA_6: 5’-TTCGGAATGATGAGCACACAA-3’, 
Hs_Rac1_6: 5’-ATGCATTTCCTGGAGAATATA-3’, 
and Hs_Cdc42_7: 5’-CATCAGATTTGAAATATTTAA-3’. 
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Cells were transfected with the siRNA at a final concentration of 10nM using 
HiPerfect (Qiagen) as described by the manufacturer. Control cells were transfected 
with siRNA sequences targeting GL2 Luciferase (Qiagen). After 72 hours, protein 
levels in total cell lysates were pulled down and/or analyzed by western blotting 
using the appropriate antibodies. Also, the effect of the corresponding knockdown 
was studied. 
 
2.4. Cell transfection with vectors 
 
Cells were transfected with 5g GFP-StarD13, or empty control vectors using 
Lipfectamine LTX with Plus reagent (Invitrogen), as described by the manufacturer. 
Cells were incubated with the transfection complexes for 5 hours then refed with 
DMEM including 30% FBS. The experiments were carried 24 hours after transfection.  
The GFP-StarD13 construct was a generous gift from Dr. Hitoshi Yagisawa 
from the University of Hyogo, Japan.  
The constructs were transformed into One Shot TOP10 chemically competent 
E. coli (Invitrogen), after which they were grown on selective media containing the 
appropriate antibiotic. The vectors were then extracted using MaxiPrep plasmid 
extraction kit (Qiagen). 
 
2.5. Western blotting 
 
Cell lysates were prepared by scraping the cells in a sample buffer consisting of 
4% SDS, 10% β-mercaptoethanol, 20% glycerol, 0.004% bromophenol blue, and 
0.125M Tris-HCl at a pH of 6.8. The resulting lysates were boiled for 5 minutes. 
Protein samples were separated by SDS-PAGE on 8% (for StarD13) or 15% (for 
RhoA and Rac) gels and transferred to PVDF membranes overnight at 30V. The 
membranes were then blocked with 5% non-fat dry milk in PBS containing 0.1% 
Tween-20 for 1 hour at room temperature and incubated with primary antibody at a 
concentration of 1:1000 for 2 hours at room temperature. After the incubation with the 
primary antibody, the membranes were washed and incubated with secondary antibody 
at a concentration of 1:2000 for 1 hour at room temperature. The membranes were then 
washed, and the bands visualized by treating the membranes with western blotting 
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chemiluminescent reagent ECL (GE Healthcare). The results were obtained on an X-
ray film (Agfa Healthcare). The levels of protein expression were compared by 
densitometry using the ImageJ software.  
 
2.6. RT-PCR 
 
Cells were grown in 6-well plates at density of 1x10
6
cells/mL and were 
transfected by either control or StarD13 siRNA for 72hrs.  Total RNA was extracted 
using the RNeasy extraction kit (Qiagen) according to the manufacturer’s instruction. 
Reverse transcriptase polymerase chain reaction (RT-PCR) was used to 
amplify RNA of StarD13.  2µg of RNA was converted to cDNA using the OneStep 
RT-PCR kit (Qiagen) as described by the manufacturer. Briefly, gene-specific 
primers designed to detect cDNA were obtained from TIB-MolBiol with the 
following sequences: Forward: 5'-AGCCCCTGCCTCAAAGTATT-3', Reverse: 5'-
AGCCCCTGCCTCAAAGTATT-3'. 
β-actin was used as a control with primers obtained from Sigma-Aldrich having the 
following sequences: Forward: 5’-ATGAAGATCCTGACCGAGCGT-3’, Reverse: 
5’-AACGCAGCTCAGTAACAGT-CCG-3’. 
Primers were used at a final concentration of 0.6µM. Primers were added to 5X 
Qiagen OneStep RT-PCR buffer providing a final concentration of 2.5mM MgCl2 in 
the reaction mix. A final concentration of 400µM of each dNTP was added along 
with 2.0µl/reaction of enzyme mix. Final mastermix volume was adjusted to 50µl 
using RNase-free water. 
Thermal cycler conditions, for both reverse transcription and PCR, was 
programmed as follows: reverse transcription at 50
o
C for 30min, initial PCR 
activation step at 95
o
C for 15min, followed by 25 cycles of denaturation at 94
o
C for 
1min, annealing for StarD13 at 50
o
C, for actin 50°C, for TGFα 48°C, and for TGFβ 
50°C for 1min and extension at 72
o
C for 1min followed by a final extension step at 
72
o
C for 10min. 
10µl of the PCR products were run on 1% agarose gel stained with ethidium 
bromide at 100V for 30min. The resulting bands were visualized under UV light and 
photographed. β-actin was used as a loading control. 
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2.7. Trypan blue exclusion method 
 
Cells were grown in 24-well plates (growth area: 2cm
2
) at a density of 
2x10
6
cells/ml. Depending on the experiment, cells were transfected with either 
StarD13 siRNA or GFP-StarD13 construct.  Following treatment period, the 
supernatant from each well was collected, cells were washed with PBS, and the PBS 
washes were added to the supernatant of each well. Cells were then trypsinized and 
collected separately from the well contents and PBS. 20µl from each collection tube 
was mixed with 20µl of Trypan Blue. 10µl of this mixture was placed in a counting 
chamber under the microscope, and the number of living and dead cells was recorded 
accordingly. For each well, two countings were done separately, PBS washes/well 
supernatant and trypsinized cells.  Under the microscope, dead cells appear blue, 
since they are permeable to Trypan Blue, while viable cells exclude the stain thus 
appearing bright.  The percentage of dead cells was reported. 
 
2.8. Cell proliferation reagent (WST-1) 
 
Cells were seeded in 96-well plates (growth area: 0.6cm
2
) at a concentration 
of 1x10
6
cells/mL. Depending on the experiment, cells were transfected with either 
StarD13 siRNA or GFP-StarD13 construct with appropriate controls. Following 
treatment period, 10µl of Cell Proliferation Reagent (WST-1; Roche, Germany) was 
added to each well. The plates were incubated at in a humidified incubator (37°C) in 
95% air and 5% CO2 for 2 hours. WST-1 is a tetrazolium salt that on contact with 
metabolically active cells is cleaved to produce formazan dye by mitochondrial 
dehydrogenases. Quantitation of formazan is done colorimetrically at 450nm. The 
absorbance of the each blank well was subtracted from the corresponding sample 
well. The results were normalized to the corresponding controls, and the percent of 
cell proliferation was reported. 
 
2.9. Cell proliferation kit I (MTT) 
 
Cells were cultured in 96-well flat bottom microplates (100μL/well) in a 
humidified incubator for 72h at 37°C after treatment. 10μL of the MTT labelling 
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reagent was added to each well and then incubated for 4h. Afterwards, 100μL of the 
Solubilization solution is added per well and the plate incubated overnight. MTT is a 
tetrazolium salt that forms formazan when in contact with metabolically active cells. 
Quantitation of formazan is done colorimetrically, using ELISA, at 595nm. The 
absorbance of the each blank well was subtracted from the corresponding sample 
well. The results were normalized to the corresponding controls, and the percent of 
cell proliferation was reported. 
 
2.10. Immunostaining 
 
Cells were plated on cover slips, and the appropriate treatment was applied. 
They were then fixed with 4% paraformaldehyde for 10 minutes, and permeabilized 
with 0.5% Triton-X100 for 10 minutes. To decrease background fluorescence, cells 
were rinsed with 0.1M glycine then incubated with 0.1M glycine for 10 minutes. For 
blocking, cells were incubated 4 times with 1% BSA, 1% FBS in PBS for 5 minutes. 
Samples were stained with primary antibodies for 2 hours and with fluorophore-
conjugated secondary antibodies for 2 hours. Fluorescent images were taken using a 
60X objective on a fluorescent microscope. 
 
2.11. Pull down assay 
 
Cells were lysed and incubated with GST-CRIB or GST-RBD and the pull-
down assay performed using the RhoA/Rac1/Cdc42 Activation Assay Combo Kit 
(Cell BioLabs) following the manufacturer’s instructions. Lysates were incubated 
with GST-RBD (for RhoA) or GST-PAK (for Rac1/Cdc42) for 1 hour at 4 °C. GTP-
RhoA, GTP-Rac1 or GTP-Cdc42 was detected by western blotting using the anti-
RhoA, anti-Rac1 or anti-Cdc42 antibodies provided in the kit. Total proteins were 
collected prior to the incubation with GST beads and used as a loading control. 
 
2.12. Wound healing assay 
 
Cells were grown to confluence on culture plates and a wound was made in the 
monolayer with a sterile pipette tip. Cells were then washed twice with PBS to remove 
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debris, and new medium was added. Phase-contrast images of the wounded area were 
taken at 0 and 24 hours after wounding. Wound widths were measured at 11 different 
points for each wound, and the average rate of wound closure was calculated in m/hr. 
 
2.13. Adhesion assay 
 
96-well plates were coated with collagen using Collagen Solution, Type I from 
rat tail (Sigma) overnight at 37°C then washed with washing buffer (0.1% BSA in 
DMEM). The plates were then blocked with 0.5% BSA in DMEM at 37°C in a CO2 
incubator for 1 hour. Plates were then washed and put on ice. Meanwhile, the cells 
were trypsinized and counted to 4x10
5
cell/mL. 50L of cells were added in each well 
and incubated at 37°C in a 5% CO2 incubator for 30 minutes. The plates were shaken 
and washed 3 times. Cells were then fixed with 4% paraformaldehyde at room 
temperature for 10 minutes, washed, and stained with crystal violet (5mg/mL in 2% 
ethanol) for 10 minutes. After staining, plates were washed extensively with water, and 
left to dry completely. Crystal violet was solubilized by incubating the cells with 2% 
SDS for 30 minutes. The absorption of the plates was read at 550m using ELISA. 
 
2.14. Invasion assay 
 
Cells were transfected with either control or StarD13 siRNAs and invasion 
assay was performed 48hrs following treatment period using the collagen-based 
invasion assay (Millipore) according to manufacturer’s instructions. Briefly, 24hrs 
prior to assay, cells were starved with serum-free medium. Cells were harvested, 
centrifuged and then resuspended in quenching medium (without serum). Cells were 
then brought to a concentration of 1x10
6
cells/mL. In the meantime, inserts were 
prewarmed with 300L of serum free medium for 30min at room temperature. After 
rehydration, 250L of media was removed from inserts and 250L of cell suspension 
was added. Inserts were then placed in a 24-well plate, and 500L of complete media 
(with 10% serum) was added to the lower wells. Plates were incubated for 24hrs at 
37
o
C in a CO2 incubator. Following incubation period, inserts were stained for 20min 
at room temperature with 400L of cell stain provided with the kit. Stain was then 
extracted with extraction buffer (also provided). 100L of extracted stain was then 
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transferred to a 96-well plate suitable for colorimetric measurement using a plate 
reader. Optical Density was then measured at 560m. 
 
2.15. Statistical analysis 
 
All the results reported represent average values from three independent 
experiments. All error estimates are given as ± SEM. The p-values were calculated by 
t-tests or chi-square tests depending on the experiment using the VassarStats: Website 
for Statistical Computation (http://vassarstats.net/). All results showed stasitical 
significance with a p-value   0.05. 
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Chapter III 
RESULTS 
 
3.1. StarD13 knockdown increases colorectal cancer cell viability 
We first wanted to study the role of StarD13 on colorectal cancer cell 
viability. We knocked down StarD13 using two different siRNA oligos. The 
inhibition results were shown by western blot and RT-PCR. The loading control was 
β-actin (Figure 12A). Due to knockdown, around 38% decrease in dead cells was 
observed, using the exclusion method (Figure 12B). Correspondingly, WST-1 
reagent and MTT kit showed around 40% increase in cellular proliferation of 
transfected cells with StarD13 siRNA (Figures 12C-D). 
 
Figure 12: StarD13 knockdown increases cell viability. Control cells were 
transfected with Luciferase, while treated cells were transfected with two oligos of 
StarD13 siRNA: oligo 3 and 8. Experiments were done after 72h from transfection. 
A. After cell lysis, western blot analysis was performed for StarD13 (upper left gel) 
and for β-actin as a loading control (lower left gel). Also, StarD13 level was assessed 
through RT-PCR (upper right gel), and β-actin used as a loading control (lower right 
gel). B. Trypan blue exclusion method was done and the % dead cells was 
determined. C. WST-1 was used to determine cell proliferation. Results are 
expressed as fold increase from the control. D. Also, MTT proliferation kit was used, 
and the results are shown as fold increase from the control. (n = 3; mean ± SEM) 
* * 
* 
* 
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3.2. StarD13 overexpression decreases colorectal cancer cell 
viability 
 
Control cells were transfected with the GFP vector alone, while treated cells 
were transfected with the GFP-StarD13 vector. Cell viability was then compared 
between samples. The over-expression of StarD13 in cells led to a significant 
increase in the percentage of dead cells, using the Trypan blue exclusion method 
(Figure 13A). Consistently, a decrease of 20% and 45% in cell proliferation, using 
WST-1 reagent and MTT kit respectively, was shown (Figures 13B-C). 
 
 
Figure 13: Overexpression of StarD13 decreases cell viability. Cells were either 
transfected with GFP alone as a control, or with GFP-StarD13. Duration of the 
treatment was 24h. A. By Trypan blue exclusion method, dead cells increased by 
50%. B. Using the WST-1, a 20% decrease in cell proliferation was observed. C. A 
dramatic decrease in cell proliferation of around 45% was seen by the MTT kit. (n = 
3; mean ± SEM) 
 
  
* 
* 
* 
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3.3. Role of StarD13 in cell proliferation 
 
After studying the phenotype of cells affected by StarD13 knockdown, at the 
level of proliferation and viability, we wanted to check what is happening at the 
molecular level. We started by investigating the potential role of StarD13 in the 
TGF-α and TGF-β1 pathways. However, no significant effect was conferred (Figure 
14A-B). 
 
 
 
Figure 14: Effect of StarD13 knock down on the expression of TGF-α and TGF-
β1 mRNAs. Control cells were transfected with Luciferase, while treated cells were 
transfected with StarD13 siRNA. 72 hours after transfection, RT-PCR was 
performed with specific primers. A. β-actin was used as a loading control (lower 
gel). In both, the upper and middle gels, TGF-α and TGF-β1 expression respectively 
was not affected. B. The bands from the gels were quantified using the ImageJ 
software, and then normalized to the control. (n = 3; mean ± SEM) 
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3.4. StarD13 knockdown down regulates tumor suppressor p53 
 
Another attempt to study the mechanism by which StarD13 knockdown is 
increasing cellular proliferation was by checking the protein level of the tumor 
suppressor p53. Cells were transfected with a StarD13 siRNA for 72 hours, and then 
lysed and the total proteins extracted. Immunoblotting was performed using anti-p53 
antibody. Results show a 25% decrease in the expression level of the p53 protein 
upon StarD13 knockdown (Figure 15A-B) 
 
 
 
Figure 15: StarD13 knockdown down regulates tumor suppressor p53. Cells 
were transfected with either luciferase control siRNA or StarD13 siRNA for 72 
hours. A. Cells were then lysed and immunoblotted by western blot analysis using 
anti-p53 antibody (upper gel). The knockdown of StarD13 was successful as seen in 
the middle gel, and the loading control used was β-actin (lower gel). B. The bands 
from the gels were quantified using the ImageJ software, and then normalized to the 
control. (n = 3; mean ± SEM) 
  
* 
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3.5. StarD13 knockdown up-regulates anti-apoptotic Bcl-2 and 
down regulates pro-apoptotic protein Bax 
 
Furthermore, an important aspect was to study the effect of StarD13 
knockdown on cellular proliferation through its effect on the expression levels of the 
anti-apoptotic protein Bcl-2 and pro-apoptotic protein BAX. Cells were transfected 
with a StarD13 siRNA for 72 hours, and then lysed and the total proteins extracted. 
Immunoblotting was performed using anti-Bcl-2 and anti-BAX antibodies. Results 
show a 30% increase in the expression level of the Bcl-2 protein upon StarD13 
knockdown (upper gel), while consistently showing a 20% decrease in the level of 
BAX protein expression (second gel) (Figure 16A-B).  
 
 
Figure 16: StarD13 knockdown up-regulates anti-apoptotic protein Bcl-2 and 
down-regulates the pro-apoptotic protein BAX. Cells were transfected with either 
luciferase control siRNA or StarD13 siRNA for 72 hours. A. Cells were then lysed 
and immunoblotted by western blot analysis using anti-Bcl-2 antibody (upper gel). 
The knockdown of StarD13 was successful as seen in the middle gel, and the loading 
control used was β-actin (lower gel). B. Results were quantified using the ImageJ 
software, and then normalized to the control. (n = 3; mean ± SEM) 
* 
I 
I 
* 
I 
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3.6. StarD13 is a GAP for RhoA and Cdc42 
 
We were interested in determining the effect of StarD13 over expression on 
the activation of members of the family of RhoGTPases. For this reason, we 
performed a pull-down assay to detect the levels of active RhoA, Cdc42, and Rac1 in 
cells transfected with the siRNA as compared to the activation levels in cells 
transfected with control vectors. Results showed an 80% decrease in RhoA 
activation, a 1.5-fold decrease in Cdc42 activation, and a mild increase in Rac1 
activation (Figures 17A-B). 
 
 
Figure 17: StarD13 is a specific GAP for RhoA and Cdc42. A. Cells were 
transfected with either luciferase as control (right lanes), or StarD13 siRNA (left 
lanes). After 72 hours, cells were lysed and incubated with GST-RBD (Rhotekin 
binding domain) (upper panels), or with GST-CRIB (Cdc42 and Rac interactive 
binding domain) (middle and lower panels) to pull down active RhoA and active 
Cdc42 and Rac1 respectively. Samples were then blotted with RhoA, Cdc42, and 
Rac1 antibodies. The lower gels in each panel are western blots for the total cell 
lysates, used as loading controls. B. The bands from the active RhoA, active Cdc42, 
and active Rac1 gels were quantified using the ImageJ software, and then normalized 
to the amount of total proteins. (n = 3; mean ± SEM)  
I 
I 
I 
I 
I 
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3.7. Role of StarD13 in 2D cell motility 
 
After proving that StarD13 has a major role in cancer cell proliferation, and 
establishing that it is a Rho GAP, we then wanted to further assess its role in 2D 
motility. Thus, we knocked down StarD13 and its effect was assayed using the 
wound healing assay. Results showed a relative decrease in motility of around 1.5 
folds in terms of wound closure in cells with StarD13 knock down (4.28μm/hr) with 
respect to control cells (6.1μm/hr) (Figure 18A-B). 
 
 
 
Figure 18: Wound Healing experiment upon StarD13 knockdown. Control cells 
were transfected with Luciferase, while treated cells were transfected with StarD13 
siRNA. Wounds were done after 72hr from transfection. A. Cells from the control 
and KD were grown in plates forming a monolayer, then wounded and directly 
pictured (upper micrographs). After 20 hours, the pictures were taken at the same 
frame (lower micrographs). B. Quantitation of the wound healing experiments was 
done as following: width of each wound was measured at 11 dissimilar points, and 
their average rate of the wound closure was calculated as μm/hr. (n = 3; mean ± 
SEM) 
  
* 
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3.8. StarD13 knockdown promotes actin stress fiber formation 
 
To further investigate the phenotypic nature of cells upon StarD13 knock 
down, we immunostained control and treated cells with Rhodamin phalloidin to stain 
actin stress fibers. Results show that the knock down of StarD13 promotes the 
formation and stabilization of actin stress fibers (Figure 19). 
 
 
 
Figure 19: Role of StarD13 in actin stress fiber formation. Cells were either 
transfected with the control luciferase (left panel), or with StarD13 siRNA (right 
lane). After 72 hours, cells were fixed and immunostained using Rhodamin 
phalloidin to stain actin fibers. Micrographs were imaged using the 60x objective. 
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3.9. StarD13 knockdown increases cell adhesion to collagen 
 
Since StarD13 knockdown has showed the increase in actin stress fiber 
formation and stabilization, we next wanted to study the effect of this same knock 
down treatment on the adhesion of these colorectal cancer cells to collagen, which is 
a main component of the ECM. The results showed around a three-fold increase in 
the adhesion of these cells with knock down as compared to the control cells (Figures 
20A-B). 
 
 
 
Figure 20: StarD13 knock down increases cellular adhesion to collagen. A. 
Representative micrographs of cells fixed and stained with crystal violet to detect 
adhesion. B. Quantitation of the micrographs. Crystal violet was solubilised and the 
absorption was taken at 550μm using ELISA. Data is measured in arbitrary units and 
normalized to the control. (n = 3; mean ± SEM). 
  
* 
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3.10. Effect of RhoGTPases on cellular adhesion to collagen 
 
Given that StarD13 is a RhoGAP and has been shown to be involved in 
regulation of cellular adhesion, we studied the direct effect of three members of the 
Rho GTPase family, i.e. RhoA, Cdc42, and Rac1. The results showed a 20% 
decrease in cellular adhesion upon RhoA knockdown (Figure 21A) and around a 
25% decrease upon Cdc42 Knockdown (Figure 21B). However, the knockdown of 
Rac1 showed an antagonistic result, with a 10% increase in cellular adhesion to 
collagen (Figure 21C). 
 
 
 
Figure 21: Effect of RhoA, Cdc42, and Rac1 knockdowns on cell adhesion. A. 
Quantitation of the adhesion assay with RhoA knock down. B. Quantitation of the 
adhesion assay with Cdc42 knock down. C. Quantitation of the adhesion assay with 
Rac1 knock down. (n = 3; mean ± SEM) 
* 
* 
* 
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3.11. StarD13 knockdown increases cellular invasion 
 
After studying the effect on adhesion, we then assayed the effect of StarD13 
knock down on cellular invasion. This was an in vitro collagen-based invasion assay 
using FBS as a chemoattractant. Unlike in the results we got with the 2D motility, 
there was around a two-fold increase in cell invasion in cells with StarD13 knock 
down as compared to the control cells (Figures 22A-B). 
 
 
 
Figure 22: StarD13 knock down increases cellular invasion. A. Representative 
micrographs of invaded cells on the bottom side of the membrane stained with cell 
stain according to assay instructions. B. Cell stain was extracted and colorimetric 
measurements were taken at 560μm, using ELISA. Data is measured in arbitrary 
units and normalized to the control. (n = 3; mean ± SEM). 
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3.12. Effect of RhoA, Cdc42, and Rac1 knockdowns on cell invasion 
 
Furthermore, we studied the direct effect of three members of the Rho 
GTPase family, i.e. RhoA, Cdc42, and Rac1, on cellular invasion, with collagen as a 
chemoattractant. The results showed around a 40% decrease in cellular invasion 
upon RhoA knockdown and Cdc42 Knockdown (Figures 21A-B). However, the 
knockdown of Rac1 showed an antagonistic result, with a 10% increase in cellular 
invasion (Figure 21C). 
 
 
 
Figure 23: Effect of RhoA, Cdc42, and Rac1 knockdowns on cell invasion. A. 
Quantitation of the invasion assay with RhoA knock down. B. Quantitation of the 
invasion assay with Cdc42 knock down. C. Quantitation of the invasion assay with 
Rac1 knock down. (n = 3; mean ± SEM)  
* * 
* 
I I 
I 
 53 
 
Chapter IV 
DISCUSSION 
 
 
StarD13 was previously identified to be a tumor suppressor gene in 
hepatocellular carcinoma (Ching, et al., 2003). Later studies showed that it localizes 
to focal adhesions in HeLa cells (Kawai, et al., 2009). In this study, an overall 
characterization of StarD13 in colorectal cancer is provided, in terms of effect on 
cellular viability and proliferation, sub-cellular localization, GAP activity, and 
motility and invasion. 
 
We considered an in vitro model of colorectal cancer cell line, i.e. Caco-2 and 
HT-29, to first look at the effect of StarD13 on cell proliferation and viability. The 
silencing of StarD13 in both cell lines led to a decrease in cell death, as by the 
Trypan blue exclusion method, and an increase in cellular viability, as by the WST-1 
and MTT proliferation assays. Consistently, StarD13 overexpression using a GFP 
vector led to an increase in cell death, as by the exclusion method, and a decrease in 
cell proliferation by the WST-1 and MTT assays. This was consistent with several 
previous studies done on astrocytoma and breast cancer cell lines in our lab (El-Sitt, 
et al., 2012). Accordingly, StarD13 seems to play a role of a tumor suppressor in 
different cancers especially colorectal cancer cells, consistent with the literature. 
 
In order to explain how the silencing and over-expression of StarD13 is 
affecting cell viability and proliferation on the molecular level, we performed RT-
PCR runs, using primers specific for the mitogen TGF-α and the tumor suppressor 
TGF-β1. Contrary to our expectations, there was no effect on mRNA levels of both 
proteins. This suggests that StarD13 knockdown affects cellular viability and 
proliferation through a different pathway. Thus, to further investigate the molecular 
pathway, we evaluated the protein expression of other tumor suppressors, through 
western blot analysis, where StarD13 silencing down regulated p53 tumor suppressor 
genes. We also studied the expression of anti-apoptotic Bcl-2 protein and pro-
apoptotic BAX protein. As expected, Bcl-2 increased expression and BAX decreased 
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expression upon StarD13 knock down. These results prove the effect of StarD13 on 
colorectal cancer cellular viability, proliferation, through the regulation of tumor 
suppressor, anti-apoptotic, and pro-apoptotic proteins. 
 
Earlier studies showed that StarD13 has a GAP domain (Ullmannova & 
Popescu, 2006) and localizes to focal adhesions (Kawai, et al., 2009). In our system, 
we further confirmed its function as a Rho GAP, as detected by the increase in RhoA 
and Cdc42 activation, but the decrease in Rac1 activation upon under expression of 
StarD13. Previous studies, done in hepatocellular carcinoma, showed consistent 
results, thus supporting our findings (Xiaorong, Wei, Liyuan, & Kaiyan, 2008). 
These data suggest that StarD13 might have a role in regulating RhoA, thus might 
affect cellular motility. 
 
After performing a series of experiments regarding proliferation and viability 
of colorectal cancer cells, we then wanted to study the StarD13 on 2D cell motility. 
Indeed, knockdown of StarD13 in these cell lines inhibited cell motility. Thus, 
although it is known to be tumor suppressor, StarD13 is needed for 2D cell motility. 
This was in accordance with previous studies in our lab, where StarD13 silencing 
inhibited migration of astrocytoma and breast cancer cells (data not shown). 
Moreover, our immunostaining results showed StarD13 to promote actin stress fiber 
formation and stabilization. Nevertheless, contradictory to our results, a preceding 
study on normal endothelial cells reported that StarD13 inhibition led to an increase 
in cell migration (Lin, et al., 2010). This inconsistency can be explained by the fact 
that normal cells are exceedingly different than colorectal cancer cell systems. These 
cancer cells used in our study typically display distinct cell morphology and altered 
signaling pathways. 
 
To further investigate the inhibition of 2D cell motility due to StarD13 knock 
down, we performed an adhesion assay, which showed a major increase in the 
stabilization and adhesion of cells to collagen upon silencing StarD13. Knowing that 
StarD13 is a RhoGAP, and since RhoA has been widely proven to be indispensible 
for the formation of focal adhesions (Arjonen, Kaukonen, & Ivaska, 2011; 
Wolfenson, Henis, Geiger, & Bershadsky, 2009), and that increasing Rho activation 
stabilizes focal adhesions inhibiting cell motility (Cox, Sastry, & Huttenlocher, 2001; 
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Sander, ten Klooster, van Delft, van der Kammen, & Collard, 1999), we formulated a 
hypothesis that StarD13 knockdown is keeping RhoA active in focal adhesions. 
Thus, we were interested in looking at the dynamics of cellular adhesion after RhoA, 
Cdc42, and Rac1 knockdowns. RhoA and Cdc42 knockdowns resulted in decreased 
adhesion, while Rac1 knockdown resulted in an increase in cellular adhesion to 
collagen. Consistent to our work, studies done on breast cancer cell lines showed that 
silencing RhoA decreased cellular adhesion to collagen I (Wu, Wu, Rosenthal, Rhee, 
& Merajver, 2010). 
 
Another recent study done on normal prostate cells showed that silencing of 
DLC1 reduces migration (Shih, Takada, & Lo, 2012). In fact, recent studies done on 
DLC1 showed that DLC1 plays differential roles in regulating cell migration and 
transformation depending on its interaction with tensins (Cao, Voss, Zhao, Kaneko, 
& Li, 2012). This highlights the differential role of the DLC family of proteins as 
tumor suppressors yet needed for cell motility. A comparable dilemma is illustrated 
in a recent review on TGF- that is known to exert tumor-suppressive effects in 
normal cells yet paradoxically, in protumorigenic cells its role is reversed  
(Massagué, 2008). 
 
After determining the mechanism by which StarD13 might affect random 2D 
cell motility, it was intriguing to us to study its effect on cellular invasion, i.e. 3D 
motility. We transfected the cells with siRNA against starD13 and performed 
collagen-based transwell invasion assay. Knowing that StarD13 knockdown inhibited 
cellular motility in 2D, it was assumed that it would also inhibit cell invasion. 
However, to our ultimate surprise, silencing StarD13 had a positive effect on cellular 
invasion, despite the fact that StarD13 knockdown stabilizes focal adhesions. We 
then perforemed RhoA, Cdc42, and Rac1 knockdowns. These also resulted in 
opposing data as compared to what we got in the adhesion assay. RhoA and Cdc42 
knockdowns led to decreased invasion, while Rac1 knockdown led to an increase in 
cellular invasion. 
 
This can be explained by focal adhesions that might play an alternative role in 
cellular invasion. In fact, a modern report studied the involvement of focal adhesions 
in the degradation of the surrounding matrix. Results revealed that specifically at 
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focal adhesion sites, several cell lines degraded underlying ECM. This process was 
proved to have occurred through the proteolytic activity of MMPs and not due to 
physical tension exerted by FAs onto the matrix (Wang & Mc Niven, 2012). This 
solidifies our data with starD13 knockdown, where we typically have an increase in 
RhoA activity, thus promoting cellular invasion. Furthermore, it was formerly 
discovered that in 3D matrices, cancer cells can switch between diverse means of 
movement (Sahai & Marshall, 2002). This pertains to the interaction between 
dissimilar signaling conditions. Hence, cells can change between an elongated 
protrusive and a more rounded blebbing movement fashion. Thus in our study, the 
diminution of StarD13 amplified cellular adhesion to the ECM, obstructing 2D 
cellular migration of mesenchymal cells. Nonetheless, this was reflected in an 
increase in 3D movement, suggesting that cells tend to switch to a more amoeboid-
like motility when they cannot move in an adhesion-dependent manner. Therefore, 
the ability of tumor cells to switch between modes of motility may limit the 
effectiveness of prospective inhibitory strategies targeting particular cell 
morphology, thus promoting the selection of a different mode to escape inhibition.  
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Chapter V 
CONCLUSION 
 
 
Even though it is previously known as a tumor suppressor gene product, in 
our current study, we have described the role of StarD13 in colorectal cancer cell 
proliferation and motility, for the first time. Our results showed that StarD13 
negatively affects cellular viability and proliferation. Having a RhoGAP activity, 
StarD13 is highly involved in cellular motility. To our surprise, StarD13 has 
opposing roles in 2D and 3D motility. StarD13 knock down inhibited 2D cell 
movement by further stabilizing and forming actin stress fibers. However, this down 
regulation of StarD13 has increased both, cellular adhesion to collagen as well as 
cellular invasion, i.e. 3D movement. 
Supplementary experiments are still to be done to further study the role of 
StarD13 on proliferation and viability by flow cytometry. Other further studies 
include finding the difference of StarD13 levels in normal versus diseases colorectal 
tissues, as well as performing immunohistochemistry on those exact tissues targeting 
the different Rho GTPases (RhoA, RhoC, Rac1, Cdc42), StarD13, and others such as 
ROCK1/2, etc. Moreover, future work consists doing wound healing assays upon the 
knockdown of the different Rho GTPases. Finally, studies performed on the 
molecular level of the action of StarD13 on cell motility will be done by looking at 
the protein levels of integrins and MMPs, as well as performing matrigel 
experiments. 
  
 58 
 
BIBLIOGRAPHY 
 
Adelstein, B. A., Macaskil, P., Chan, S. F., Katelaris, P. H., & Irwig, L. (2011). Most 
bowel cancer symptoms do not indicate colorectal cancer and polyps: A 
systematic review. BMC Gastroenterology, 11(65), 1-10. 
Alberts, A. S. (2001). Identification of a carboxyl-terminal diaphanous-related 
formin homology protein autoregulatory domain. The Journal of Biological 
Chemistry, 276(4), 2824-2830. 
Alberts, B., Johnson, A., Lewis, J., Raff, M., Roberts, K., & Walter, P. (2002). 
Molecular biology of the cell (4
th
 ed.). Retrieved from 
http://www.ncbi.nlm.nih.gov/books/NBK21054/ 
Alpers, D. H., Kalloo, A. N., Owyang, C., Powell, D. W., & Kaplowitz, N. (2009). 
Approach to screening for colorectal cancer. In T. Yamad, D. H. Alpers, A. 
N. Kalloo, & D. W. Powell, Principles of clinical gastroenterology (5
th
 ed., 
pp. 380-382). Oxford, England: Wiley-Blackwell. 
Amersi, F., Stamos, M. J., & Ko, C. Y. (2004). Palliative care for colorectal cancer. 
Surgical Oncology Clinics of North America, 13(3), 467-477. 
Ananthakrishnan, R., & Ehrlicher, A. (2007). The forces behind cell movement. 
International Journal of Biological Sciences, 3(5), 303-317. 
Arjonen, A., Kaukonen, R., & Ivaska, J. (2011). Filopodia and adhesion in cancer 
cell motility. Cell Adhesion and Migration, 5(5), 421-430. 
Artym, W., Zhang, Y., Seillier-Moiseiwitsch, F., Yamada, K. M., & Mueller, S. C. 
(2006). Dynamic interactions of cortactin and membrane type 1 matrix 
metalloproteinase at invadopodia: Defining the stages of invadopodia 
formation and function. Cancer Research, 66(6), 3034-3043. 
Astin, M., Griffin, T., Neal, R. D., Rose, P., & Hamilton, W. (2011). The diagnostic 
value of symptoms for colorectal cancer in primary care: A systematic 
review. British Journal of General Practice, 61(586), 231-243. 
Astler, V. B., & Coller, F. A. (1954). The prognostic significance of direct extension 
of carcinoma of the colon and rectum. Annals of Surgery, 139(6), 846-851. 
Aznavoorian, S., Murphy, A. N., Stetler-Stevenson, W. G., & Liotta, L. A. (1993). 
Molecular aspects of tumor cell invasion and metastasis. Cancer, 71(4), 
1368-383. 
Backer, J. M. (2008). The regulation and function of class III PI3Ks: Novel roles for 
Vps34. Biochemical Journal, 410(1), 1-17. 
Bafandeh, Y., Khoshbaten, M., Eftekhar Sadat, A. T., & Farhanq, S. (2008). Clinical 
predictors of colorectal polyps and carcinoma in a low prevalence region: 
Results of a colonoscopy based study. World Journal of Gastroenterology, 
14(10), 1534-1538. 
 59 
 
Bagrodias, S., Taylor, S. J., Jordan, K. A., Van Aelst, L., & Cerione, R. A. (1998). A 
novel regulator of p21-activated kinases. The Journal of Biological 
Chemistry, 273(37), 23633-23636. 
Bailly, M., Condeelis, J. S., & Segall, J. E. (1998). Chemoattractant-induced 
lamellipod extension. Microscopy Research and Technique, 43(5), 433-443. 
Bailly, M., Yan, L., Whitesides, G. M., Condeelis, J. S., & Segall, J. E. (1998). 
Regulation of protrusion shape and adhesion to the substratum during 
chemotactic responses of mammalian carcinoma cells. Experimental Cell 
Research, 241(2), 285-299. 
Boettner, B., & Van Aelst, L. (2002). The role of Rho GTPases in disease 
development. Gene, 286(2), 155-174. 
Bokoch, G. M. (2003). Biology of the p21-activated kinases. Annual Review of 
Biochemistry, 72(1), 743-781. 
Brabletz, T., Hlubek, F., Spaderna, S., Schmalhofer, O., Hiendelmeyer, E., Jung, A., 
& Kirchner, T. (2005). Invasion and metastasis in colorectal cancer: 
Epithelial-mesenchymal transition, mesenchymal-epithelial transition, stem 
cells and beta-catenin. Cells, Tissues, Organs, 179(1-2), 56-65. 
Bravo-Cordero, J. J., Oser, M., Chen, X., Eddy, R., Hodgson, L., & Condeelis, J. 
(2011). A novel spatiotemporal RhoC activation pathway locally regulates 
cofilin activity at invadopodia. Current Biology, 21(8), 635-644. 
Brown, C., Lain, S., Verma, C. S., Fersht, A. R., & Lane, D. P. (2009). Awakening 
guardian angels: Drugging the p53 pathway. Nature Review Cancer, 9(12), 
862-873. 
Burbelo, P. D., & Drechsel, D. (1995). A conserved binding motif defines numerous 
candidate target proteins for both Cdc42 and Rac GTPases. The Journal of 
Biological Chemistry, 270(49), 29071-29074. 
Burridge, K., & Wennerberg, K. (2004). Rho and Rac take center stage. Cell, 116(2), 
167-179. 
Bustelo, X. R. (2000). Regulatory and signaling properties of the Vav family. 
Molecular and Cellular Biology, 20(5), 1461-1477. 
Calvo, F., & Sahai, E. (2011). Cell communication networks in cancer invasion. 
Current Opinion in Cell Biology, 23(5), 621-629. 
Cancer Genome Atlas Network. (2012). Comprehensive molecular characterization 
of human colon and rectal cancer. Nature, 487(7407), 330-337. 
Cao, X., Voss, C., Zhao, B., Kaneko, T., & Li, S. S. (2012). Differential regulation of 
the activity of deleted in liver cancer 1 (DLC1) by tensins controls cell 
migration and transformation. Proceedings of the National Academy of 
Sciences, 109(12), 4708-4718. 
 60 
 
Cary, L. A., Han, D. C., Polte, T. R., Hanks, S. K., & Guan, J. L. (1998). 
Identification of p130Cas as a mediator of focal adhesion kinase-promoted 
cell migration. Journal of Cell Biology, 140(1), 211-221. 
Chakravarthi, S., Krishnan, B., & Madhavan, M. (1999). Apoptosis and expression 
of p53 in colorectal neoplasms. Indian Journal of Medical Research, 86(7), 
95-102. 
Chial, H. (2008). Proto-oncogenes to oncogenes to cancer. Nature Education, 1(1), 
23-44. 
Childs, G. V. (2001). The actin cytoskeleton. University of Arkansas for Medical 
Sciences. Retrieved from http://www.cytochemistry.net/Cell-
biology/actin_filaments_intro.htm 
Ching, Y. P., Wong, C. M., Chan, S. F., Leung, T. H., Ng, D. C., Jin, D. Y., & Ng, I. 
O. (2003). Deleted in liver cancer (DLC) 2 encodes a RhoGAP protein with 
growth suppressor function and is underexpressed in hepatocellular 
carcinoma. The Journal of Biological Chemistry, 278(12), 10824-10830. 
Chung, H. H., & Jang, B. I. (2013). A perspective role of targeted therapy in colon 
cancer. Korean Journal of Gastroenterology, 61(3), 128-135. 
Clark, E. A., Golub, T. R., Lander, E. S., & Hynes, R. O. (2000). Genomic analysis 
of metastasis reveals an essential role for RhoC. Nature, 406(6795), 532-535. 
Collins, I., & Garrett, M. D. (2005). Targeting the cell division cycle in cancer: CDK 
and cell cycle checkpoint kinase inhibitors. Current Opinion in 
Pharmacology, 5(4), 366-373. 
Condeelis, J. S. (2001). How is actin polymerization nucleated in vivo? Trends in 
Cell Biology, 11(7), 288-293. 
Condeelis, J. S., Wyckoff, J. B., Bailly, M., Pestell, R., Lawrence, D., Backer, J., & 
Segall, J. E. (2001). Lamellipodia in invasion. Seminars in Cancer Biology, 
11(2), 119-128. 
Condeelis, J., & Segall, J. E. (2003). Intravital imaging of cell movement in tumours. 
Nature Review Cancer, 3(12), 921-930. 
Cooper, K., Squires, H., Carroll, C., Papaioannou, D., Booth, A., Logan, R. F., . . . 
Tappenden, P. (2010). Chemoprevention of colorectal cancer: Systematic 
review and economic evaluation. Health Technology Assessment, 1(1), 1-206. 
Cox, E. A., Sastry, S. K., & Huttenlocher, A. (2001). Integrin-mediated adhesion 
regulates cell polarity and membrane protrusion through the Rho family of 
GTPases. Molecular Biology of the Cell, 12(2), 265-277. 
Crespo, P., Schuebel, K., Ostrom, A. A., Gutkind, J. S., & Bustelo, X. R. (1997). 
Phosphotyrosine-dependent activation of Rac-1 GDP/GTP exchange by the 
vav proto-oncogene product. Nature, 385(6612), 169-172. 
 61 
 
Croce, C. M. (2008). Oncogenes and cancer. The New England Journal of Medicine, 
358(5), 502-511. 
Cunningham, D., Atkin, W., Lenz, H.-J., Lynch, H., Minsky, B., Nordlinger, B., & 
Starling, N. (2010). Colorectal cancer. Lancet, 375(9719), 1030-1047. 
Danciu, M., & Mihailovici, M. S. (2010, February 3). Gastrointestinal tract 
pathology. Atlas of Pathology. Retrieved from http://www.pathologyatlas.ro/ 
Das, B., Shu, X., Day, G. J., Han, J., Krishna, U. M., & Falck, J. R. (2000). Control 
of intramolecular interactions between the pleckstrin homology and Dbl 
homology domains of Vav and Sos1 regulates Rac binding. The Journal of 
Biological Chemistry, 275(20), 15074-15081. 
Dbouk, H. A., & Backer, J. M. (2010). A beta version of life: p110β takes center 
stage. Oncotarget, 1(8), 729-733. 
DeMali, K. A., & Burridge, K. (2003). Coupling membrane protrusion and cell 
adhesion. Journal of Cell Science, 116, 2389-2397. 
DerMardirossian, C., & Bokoch, G. M. (2005). GDIs: Central regulatory molecules 
in Rho GTPase activation. Trends in Cell Biology, 15(7), 356-363. 
Desch, C. E., Benson, A. B., Somerfield, M. R., Flynn, P. J., Krause, C., Loprinzi, C. 
L., . . . Oncology, A. S. (2005). Colorectal cancer surveillance: 2005 update 
of an American Society of Clinical Oncology practice guideline. Journal of 
Clinical Oncology, 23(33), 8512-8519. 
Devita, V. T., Lawrence, T. S., & Rosenberg, S. A. (2008). DeVita, Hellman, and 
Rosenberg's Cancer: Principles and practice of oncology (Vol. 1). 
Philadelphia: Lippincott Williams & Wilkins, a Walters Kluwer Business. 
Doyle, V. C. (2007). Nutrition and colorectal cancer risk: A literature review. 
Gastroenterology Nursing, 30(3), 178-182. 
Du, W., & Prendergast, G. C. (1999). Geranylgeranylated RhoB mediates 
suppression of human tumor cell growth by farnesyltransferase inhibitors. 
Cancer Research, 59(21), 5492-5496. 
Dukes, C. E. (1932). The classification of cancer of the rectum. Journal of Pathology 
and Bacteriology, 35(3), 323-332. 
Durkin, M. E., Yuan, B. Z., Zhou, X., Zimonjic, D. B., Lowy, D. R., Thorgeirsson, S. 
S., & Popescu, N. C. (2007). DLC-1: A Rho GTPase-activating protein and 
tumour suppressor. Journal of Cellular and Molecular Medicine, 11(5), 
1185-1207. 
Edwards, D. C., Sanders, L. C., Bokoch, G. M., & Gill, G. N. (1999). Activation of 
LIM-kinase by Pak1 couples Rac/Cdc42 GTPase signalling to actin 
cytoskeletal dynamics. Nature Cell Biology, 1(5), 253-259. 
 62 
 
El Zouhairi, M., Charabaty, A., & Pishvaian, M. J. (2011). Molecularly targeted 
therapy for metastatic colon cancer: Proven treatments and promising new 
agents. Gastrointestine Cancer Research, 4(1), 15-21. 
El-Sibai, M., Nalbant, P., Pang, H., Flinn, R. J., Sarmiento, C., Macaluso, F., . . . 
Backer, J. M. (2007). Cdc42 is required for EGF-stimulated protrusion and 
motility in MTLn3 carcinoma cells. Journal of Cell Science, 120(Pt 19), 
3465-3472. 
El-Sibai, M., Pertz, O., Pang, H., Yip, S. C., Lorenz, M., Symons, M., . . . Backer, J. 
M. (2008). RhoA/ROCK-mediated switching between Cdc42- and Rac1-
dependent protrusion in MTLn3 carcinoma cells. Experimental Cell 
Research, 14(7), 1540-1552. 
El-Sitt, S., Khalil, B. D., Hanna, S., El-Sabban, M., Fakhreddine, N., & El-Sibai, M. 
(2012). DLC2/StarD13 plays a role of a tumor suppressor in astrocytoma. 
Oncology Reports, 28(2), 511-518. 
Engelman, J. A., Luo, J., & Cantley, L. C. (2006). The evolution of 
phosphatidylinositol 3-kinases as regulators of growth and metabolism. 
Nature Reviews. Genetics, 7(8), 606-619. 
Etienne-Manneville, S., & Hall, A. (2002). Rho GTPases in cell biology. Nature, 
420(6916), 629-635. 
Evans, V. G. (1993). Multiple pathways to apoptosis. Cell Biology International, 
17(5), 461-476. 
Fang, J. Y., & Richardson, B. C. (2005). The MAPK signalling pathways and 
colorectal cancer. Lancet Oncology, 6, 322-327. 
Fedirko, V., Tramacere, I., Bagnardi, V., Rota, M., Scotti, L., Islami, F., . . . Jenab, 
M. (2011). Alcohol drinking and colorectal cancer risk: An overall and dose-
response meta-analysis of published studies. Annals of Oncology, 22(9), 
1958-1972. 
Ferlay, J., Shim, H.-R., Bray, F., Forman, D., Mathers, C., & Parkin, D. M. (2010). 
Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. 
International Journal of Cancer, 127(1), 2893-2917. 
Figueredo, A., Rumble, B. R., Maroun, J., Earle, C. C., Cummings, B., Mc Leod, R., 
. . . Zwaal, C. (2003). Follow-up of patients with curatively resected 
colorectal cancer: A practice guideline. BMC Cancer, 3(26), 1-23. 
Gad, A. K., & Aspenström, P. (2010). Rif proteins take to the RhoD: Rho GTPases at 
the crossroads of actin dynamics and membrane trafficking. Cellular 
Signalling, 22(2), 183-189. 
Garcia-Mata, R., Boulter, E., & Burridge, K. (2011). The 'invisible hand': Regulation 
of RHO GTPases by RHOGDIs. Nature Reviews Molecular Cell Biology, 12, 
493-504. 
 63 
 
Gertler, F., & Condeelis, J. (2011). Metastasis: Tumor cells becoming MENAcing. 
Trends in Cell Biology, 21(2), 81-90. 
Giannoulis, K., Fountzilas, G., Angouridakis, N., Angouridaki, C., Giannoulis, E., & 
Gamuros, O. (2004). Serum levels of bcl-2 in patients with colorectal cancer. 
Techniques in Coloproctology, 8(Supplementary 1), 56-58. 
Grise, F., Bidaud, A., & Moreau, V. (2009). Rho GTPases in hepatocellular 
carcinoma. Biochimica et Biophysica Acta, 1795(2), 137-151. 
Guttridge, D. C., Albanese, C., Reuther, J. Y., Pestell, R. G., & Baldwin, A. S. 
(1999). NF-kappaB controls cell growth and differentiation through 
transcriptional regulation of cyclin D1. Molecular and Cellular Biology, 
19(8), 5785-5799. 
Half, E., Bercovich, D., & Rozen, P. (2009). Familial adenomatous polyposis. 
Orphanet Journal of Rare Diseases, 4(22), 1-23. 
Hall, A. (1998). Rho GTPases and the actin cytoskeleton. Science, 279(5350), 509-
514. 
Harrington, E. A., Fanidi, A., & Evan, G. I. (1994). Oncogenes and cell death. 
Current Opinion in Genetics and Development, 4(1), 120-129. 
Harriss, D. J., Atkinson, G., Batterham, A., George, K., Cable, N. T., Reilly, T., . . . 
Renehan, A. G. (2009). Lifestyle factors and colorectal cancer risk (2): A 
systematic review and meta-analysis of associations with leisure-time 
physical activity. Colorectal Disease, 11(7), 689-701. 
He, J., & Efron, J. E. (2011). Screening for colorectal cancer. Advances in Surgery, 
45, 31-44. 
Henderson, B. R., & Fagotto, F. (2002). The ins and outs of APC and beta-catenin 
nuclear transport. EMBO Reports, 3(9), 834-839. 
Hoyle, M., Crathorne, L., Peters, J., Jones-Hughes, T., Cooper, C., Napier, M., . . . 
Hyde, C. (2013). The clinical effectiveness and cost-effectiveness of 
cetuximab (mono- or combination chemotherapy), bevacizumab 
(combination with non-oxaliplatin chemotherapy) and panitumumab 
(monotherapy) for the treatment of metastatic colorectal cancer after first-lin. 
Health Technology Assessment, 17(14), 1-237. 
Ionov, Y., Peinado, M. A., Malkhosyan, S., Shibata, D., & Perucho, M. (1993). 
Ubiquitous somatic mutations in simple repeated sequences reveal a new 
mechanism for colonic carcinogenesis. Nature, 363(6429), 558-561. 
Jaffe, A. B., & Hall, A. (2005). Rho GTPases: Biochemistry and biology. Annual 
Review of Cell and Developmental Biology, 21, 247-269. 
Jansson, A., & Sun, X. F. (2002). Bax expression decreases significantly from 
primary tumor to metastasis in colorectal cancer. Journal of Clinical 
Oncology, 20(3), 811-816. 
 64 
 
Jawad, N., Direkzen, N., & Leedham, S. J. (2011). Inflammatory bowel disease and 
colon cancer. Recent Results in Cancer Research, 185(1), 99-115. 
Jellema, P., van der Windt, D. A., Bruinvels, D. J., Mallen, C. D., van Weyenberg, S. 
J., Mulder, C. J., & de Vet, H. C. (2010). Value of symptoms and additional 
diagnostic tests for colorectal cancer in primary care: Systematic review and 
meta-analysis. British Medical Journal, 340(1269), 1-21. 
Jemal, A., Bray, F., Center, M. M., Ward, E., & Forman, D. (2011). Global cancer 
statistics. CA: Cancer Journal for Clinicians, 61(2), 69-90. 
Johnson, D. I. (1999). Cdc42: An essential Rho-type GTPase controlling eukaryotic 
cell polarity. Microbiology and Molecular Biology Reviews, 63(1), 54-105. 
Joyce, D., Bouzahzah, B., Fu, M., Albanese, C., D'Amico, M., Steer, J., . . . Pestell, 
R. G. (1999). Integration of Rac-dependent regulation of Cyclin D1 
transcription through a Nuclear Factor-κB-dependent pathway. The Journal 
of Biological Chemistry, 274(36), 25245-25249. 
Juhn, E., & Khachemoune, A. (2010). Gardner syndrome: Skin manifestations, 
differential diagnosis and management. American Journal of Clinical 
Dermatology, 11(2), 117-122. 
Kanoh, S., & Rubin, B. K. (2010). Mechanisms of action and clinical application of 
macrolides as immunomodulatory medications. Clinical Microbiology 
Reviews, 23(3), 590-615. 
Kaverina, I., Krylyshkina, O., & Small, J. V. (2002). Regulation of substrate 
adhesion dynamics during cell motility. The International Journal of 
Biochemistry and Cell Biology, 34(7), 746-761. 
Kawai, K., Seike, J., Iion, T., Kiyota, M., Iwamae, Y., Nishitani, H., & Yagisawa, H. 
(2009). START-GAP2/DLC2 is localized in focal adhesions via its N-
terminal region. Biochemical and Biophysical Research Communication, 
380(4), 736-741. 
Kawasaki, H., Altieri, D. C., Lu, C. D., Toyoda, M., Tenjo, T., & Tanigawa, N. 
(1998). Inhibition of apoptosis by Survivin predicts shorter survival rates in 
colorectal cancer. Cancer Research, 58, 5071-5074. 
Keely, P. J., Westwick, J. K., Whitehead, I. P., Der, C. J., & Parise, L. V. (1997). 
Cdc42 and Rac1 induce integrin-mediated cell motility and invasiveness 
through PI(3)K. Nature, 390(6660), 632-636. 
Khalil, B. D., & El-Sibai, M. (2012). Rho GTPases in primary brain tumor 
malignancy and invasion. Journaal of Neurooncology, 108(3), 333-339. 
Kim, Y. S., Liotta, L. A., & Kohn, E. C. (1993). Cancer invasion and metastasis. 
Hospital Practice (office ed.), 28(5), 92-96. 
 65 
 
Kimura, K., Ito, M., Amano, M., Chihora, K., Fukata, Y., Nakafuku, M., . . . 
Kaibuchi, K. (1996). Regulation of myosin phosphatase by Rho and Rho-
associated kinase (Rho-kinase). Science, 273(5272), 245-248. 
Klemke, R. L., Leng, J., Molander, R., Brooks, P. C., Vuori, K., & Cheresh, D. A. 
(1998). CAS/Crk coupling serves as a "molecular switch" for induction of 
cell migration. Journal of Cell Biology, 140(4), 961-972. 
Lauffenburger, D. A., & Horwitz, A. F. (1996). Cell migration: A physically 
integrated molecular process. Cell, 84(3), 359-369. 
Lee, I. M., Shiroma, E. J., Lobelo, F., Puska, P., Blair, S. N., Katzmarzyk, P. T., & 
Group, L. P. (2012). Effect of physical inactivity on major non-
communicable diseases worldwide: An analysis of burden of disease and life 
expectancy. Lancet, 380(9838), 219-229. 
Leung, T. H.-Y., Ching, Y. P., Yam, J. W., Wong, C. M., Yau, T. O., Jin, D. Y., & 
Ng, I. O.-L. (2005). Deleted in liver cancer 2 (DLC2) suppresses cell 
transformation by means of inhibition of RhoA activity. Proceedings of the 
National Academy of Sciences of the United States of America, 102(42), 
15207-15212. 
Levine, A. J., Momand, J., & Finlay, C. A. (1991). The p53 tumour suppressor gene. 
Nature, 351(6326), 453-456. 
Liao, Y. C., & Lo, S. H. (2008). Deleted in liver cancer-1 (DLC-1): A tumor 
suppressor not just for liver. International Journal of Biochemistry and Cell 
Biology, 40(5), 843-847. 
Lin Koo, S., Wen, J. H., Hillmer, A., Cheah, P. Y., Tan, P., & Tan, I. B. (2013). 
Current and emerging surveillance strategies to expand the window of 
opportunity for curative treatment after surgery in colorectal cancer. Expert 
Review of Anticancer Therapy, 13(4), 439-450. 
Lin, Y., Chen, N. T., Shih, Y. P., Liao, Y. C., Xue, L., & Lo, S. H. (2010). DLC2 
modulates angiogenic responses in vascular endothelial cells by regulating 
cell attachment and migration. Oncogene, 29(20), 3010-3016. 
Lopez-Lago, M., Lee, H., Cruz, C., Movilla, N., & Bustelo, X. R. (2000). Tyrosine 
phosphorylation mediates both activation and downmodulation of the 
biological activity of Vav. Molecular and Cellular Biology, 20(5), 1678-
1691. 
Ma, Y., Zhang, P., Wang, F., Yang, J., Liu, Z., & Qin, H. (2011). Association 
between vitamin D and risk of colorectal cancer: A systematic review of 
prospective studies. Journal of Clinical Oncology, 29(28), 3775-3782. 
Macias, M. J., Musacchio, A., Ponstingl, H., Nilges, M., Saraste, M., & Oschkinat, 
H. (1994). Structure of the pleckstrin homology domain from beta-spectrin. 
Nature, 1(1), 675-677. 
 66 
 
Maddika, S., Ande, S. R., Panigrahi, S., Paranjothy, T., Weglarczyk, K., Zuse, A., . . 
. Los, M. (2007). Cell survival, cell death and cell cycle pathways are 
interconnected: Implications for cancer therapy. Drug Resistance Updates, 
10(1-2), 13-29. 
Magee, A. I., Newman, C. M., Giannakouros, T., Hancock, J. F., Fawell, E., & 
Armstrong, J. (1992). Lipid modifications and function of the ras superfamily 
of proteins. Biochemical Society Transactions, 20(2), 497-499. 
Manser, E., Leung, T., Salihuddin, H., Zhao, Z. S., & Lim, L. (1994). A brain 
serine/threonine protein kinase activated by Cdc42 and Rac1. Nature, 
367(6458), 40-46. 
Markowitz, S. (2000). DNA repair defects inactivate tumor suppressor genes and 
induce hereditary and sporadic colon cancers. Journal of Clinical Oncology, 
18(21 Supplementary), 75S-80S. 
Markowitz, S. D., & Bertagnolli, M. M. (2009). Molecular origins of cancer: 
Molecular basis of colorectal cancer. The New England Journal of Medicine, 
361(25), 2449-2460. 
Marshall, M. S. (1993). The effector interactions of p21ras. Trends in Biochemical 
Sciences, 18(7), 250-254. 
Massagué, J. (2008). TGFbeta. Cancer Cell, 134(2), 215-230. 
Matsuda, M., Ota, S., Tanimura, R., Nakamura, K., Takenawa, T., Nagashima, K., & 
Kurata, T. (1996). Interaction between the amino-terminal SH3 domain of 
CRK and its natural target proteins. The Journal of Biological Chemistry, 
271(24), 14468-14472. 
McHardy, L. M., Warabi, K., Anderson, R. J., Roskelley, C. D., & Roberge, M. 
(2005). Strongylophorine-26, a Rho-dependent inhibitor of tumor cell 
invasion that reduces actin stress fibers and induces nonpolarized 
lamellipodial extensions. Molecular Cancer Therapeutics, 4(5), 772-778. 
Mehlen, P., & Fearon, E. R. (2004). Role of the dependence receptor DCC in 
colorectal cancer pathogenesis. Journal of Clinical Oncology, 22(16), 3420-
3428. 
Merika, E., Saif, M. W., Katz, A., Syrigos, C., & Morse, M. (2010). Colon cancer 
vaccines: An update. In Vivo, 24(5), 607-628. 
Moon, S. Y., & Zheng, Y. (2003). Rho GTPase-activating proteins in cell regulation. 
Trends in Cell Biology, 13(1), 13-22. 
Morra, L., & Moch, H. (2011). Periostin expression and epithelial-mesenchymal 
transition in cancer: A review and an update. Virchows Archiv, 459(5), 465-
475. 
 67 
 
Muñoz-Pinedo, C. (2012). Signaling pathways that regulate life and cell death: 
Evolution of apoptosis in the context of self-defense. Advances in 
Experimental Medicine and Biology, 738(8), 124-143. 
Murray, G., Duncan, M. E., O'Neil, P., Melvin, W. T., & Fothergrill, J. E. (1996). 
Matrix metalloproteinase−1 is associated with poor prognosis in colorectal 
cancer. Nature Medicine, 2, 461-462. 
Ng, D. C., Chan, S. F., Kok, K. H., Yam, J. W., Ching, Y. P., Ng, I. O., & Jin, D. Y. 
(2006). Mitochondrial targeting of growth suppressor protein DLC2 through 
the START domain. FEBS Letters, 580(1), 191-198. 
Nieto, M. A. (2011). The ins and outs of the epithelial to mesenchymal transition in 
health and disease. Annual Review of Cell and Developmental Biology, 27, 
347-376. 
Nobes, C. D., & Hall, A. (1999). Rho GTPases control polarity, protrusion, and 
adhesion during cell movement. Journal of Cell Biology, 144(6), 1235-1244. 
Nobes, C. D., Hawkins, P., Stephens, L., & Hall, A. (1995). Activation of the small 
GTP-binding proteins rho and rac by growth factor receptors. Journal of Cell 
Science, 108(Pt 1), 225-233. 
O'Connor, K. L., Nguyen, B. K., & Mercurio, A. M. (2000). RhoA function in 
lamellae formation and migration is regulated by the alpha6beta4 integrin and 
cAMP metabolism. The Journal of Cell Biology, 148(2), 253-258. 
Olson, M., & Sahai, E. (2009). The actin cytoskeleton in cancer cell motility. 
Clinical and Experimental Metastasis, 26(4), 273-287. 
Palecek, S. P., Huttenlocher, A., Horwitz, A. F., & Lauffenburger, D. A. (1998). 
Physical and biochemical regulation of integrin releaase during rear 
detachment of migrating cells. Journal of Cell Science, 111(7), 929-940. 
Park, M. T., & Lee, S. J. (2003). Cell cycle and cancer. Journal of Biochemistry and 
Molecular Biology, 36(1), 60-65. 
Poinclous, L., Durando, X., Seitz, J. F., Thivat, E., Bardo, V. J., Giovannini, M. H., . 
. . Monges, G. (2009). Loss of Bcl-2 expression in colon cancer: A prognostic 
factor for recurrence in stage II colon cancer. Surgical Oncology, 18(4), 357-
365. 
Popescu, N. C., & Durkin, M. E. (2004). Rho GTPase activating protein cDNA on 
chromosome 13q12 is the deleted in liver cancer (DLC2) gene. Biochemical 
and Biophysical Research Communications, 315(4), 781. 
Price, L. S., Leng, J., Schwartz, M. A., & Bokoch, G. M. (1998). Activation of Rac 
and Cdc42 by Integrins mediates cell spreading. Molecular Biology of the 
Cell, 9(7), 1863-1871. 
Qaseem, A., Denberg, T. D., Hopkins, R. H., Humphrey, L. L., Levine, J., Sweet, D., 
. . . Physicians, C. G. (2012). Screening for colorectal cancer: A guidance 
 68 
 
statement from the American College of Physicians. Annals of Internal 
Medicine, 156(5), 378-386. 
Raftopoulou, M., & Hall, A. (2004). Cell migration: Rho GTPases lead the way. 
Developmental Biology, 265(1), 23-32. 
Ramaswamy, S., Nakamura, M., Vazquez, F., Batt, D. B., Perera, S., Roberts, T. M., 
& Seller, W. R. (1999). Regulation of G1 progression by the PTEN tumor 
suppressor protein is linked to inhibition of the phosphatidylinositol 3-
kinase/Akt pathway. Proceedings of the National Academy of Sciences of the 
United States of America, 96(5), 2110-2115. 
Renehan, A. G., Egger, M., Saunders, M. P., & O'Dwyer, S. T. (2002). Impact on 
survival of intensive follow up after curative resection for colorectal cancer: 
Systematic review and meta-analysis of randomised trials. British Medical 
Journal, 324(7341), 813-820. 
Ridley, A. J. (2001). Rho GTPases and cell migration. Journal of Cell Science, 
114(15), 2713-2722. 
Rottner, K., Hall, A., & Small, J. V. (1999). Interplay between Rac and Rho in the 
control of substrate contact dynamics. Current Biology, 9(12), 640-648. 
Ruvolo, P. P., Deng, X., & May, W. S. (2001). Phosphorylation of Bcl2 and 
regulation of apoptosis. Leukemia, 15(4), 515-522. 
Sahai, E. (2005). Mechanisms of cancer cell invasion. Current Opinion in Genetics 
and Development, 15(1), 87-96. 
Sahai, E., & Marshall, C. J. (2002). RHO-GTPases and cancer. Nature Reviews 
Cancer, 2(2), 133-142. 
Sander, E. E., ten Klooster, J. P., van Delft, S., van der Kammen, R. A., & Collard, J. 
G. (1999). Rac downregulates Rho activity: Reciprocal balance between both 
GTPases determines cellular morphology and migratory behavior. The 
Journal of Cell Biology, 147(7), 1009-1022. 
Sanders, L. C., Matsumura, F., Bokoch, G. M., & de Lanerolle, P. (1999). Inhibition 
of myosin light chain kinase by p21-activated kinase. Science, 283(5410), 
2083-2085. 
Schafer, K. A. (1998). The cell cycle: A review. Veterinary Pathology, 35(6), 461-
478. 
Schmidt, A., & Hall, A. (2002). Guanine nucleotide exchange factors for Rho 
GTPases: Turning on the switch. Genes and Development, 16, 1587-1609. 
Sherr, C. J. (2004). Principles of tumor suppression. Cell, 116(2), 235-246. 
Shih, Y. P., Takada, Y., & Lo, S. H. (2012). Silencing of DLC1 upregulates PAI-1 
expression and reduces migration in normal prostate cells. Molecular Cancer 
Research, 10(1), 34-39. 
 69 
 
Silva, D. (2004). Signaling pathways responsible for cancer cell invasion as targets 
for cancer therapy. Current Cancer Drug Targets, 4(4), 327-336. 
Simmonds, P. C., Primrose, J. N., Colquitt, J. L., Garden, O. J., Poston, G. J., & 
Rees, M. (2006). Surgical resection of hepatic metastases from colorectal 
cancer: A systematic review of published studies. British Journal of Cancer, 
94(7), 982-999. 
Small, J. V., Stradal, T. M., & Rottner, K. (2002). The lamellipodium: where motility 
begins. Trends in Cell Biology, 12(3), 112-120. 
Srivastava, R. K., Srivastava, A. R., Korsmeyer, S. J., Nesterova, M., Cho-Chung, Y. 
S., & Longo, D. L. (1998). Involvement of microtubules in the regulation of 
Bcl2 phosphorylation and apoptosis through cyclic AMP-dependent protein 
kinase. Molecular and Cellular Biology, 18(6), 3509-3517. 
Stein, A., Atanackovic, D., & Bokemeyer, C. (2011). Current standards and new 
trends in the primary treatment of colorectal cancer. European Journal of 
Cancer, 47(3), S312-S314. 
Stetler-Stevenson, W. G., Aznavoorian, S., & Liotta, L. A. (1993). Tumor cell 
interactions with the extracellular matrix during invasion and metastasis. 
Annual Review of Cell Biology, 9, 541-573. 
Struckhoff, A. P., Rana, M. K., & Worthylake, R. A. (2011). RhoA can lead the way 
in tumor cell invasion and metastasis. Frontiers in Bioscience, 1(16), 1915-
1926. 
Takai, Y., Sasaki, T., & Matozaki, T. (2001). Small GTP-binding proteins. 
Physiological Reviews, 81(1), 153-208. 
Takaishi, K., Sasaki, T., Kameyama, T., Tsukita, S., & Takai, Y. (1995). 
Translocation of activated Rho from the cytoplasm to membrane ruffling 
area, cell-cell adhesion sites and cleavage furrows. Oncogene, 11(1), 39-48. 
Tatsuno, I., Hirai, A., & Saito, Y. (2000). Cell-anchorage, cell cytoskeleton, and 
Rho-GTPase family in regulation of cell cycle progression. Progress in Cell 
Cycle Research, 4, 19-25. 
Taylor, R. C., Cullen, S. P., & Martine, S. J. (2008). Apoptosis: Controlled 
demolition at the cellular level. Nature Reviews Molecular Cell Biology, 9(3), 
231-241. 
Thierry, J. P. (2002). Epithelial–mesenchymal transitions in tumour progression. 
Nature Reviews Cancer, 2(6), 442-454. 
Thorsell, A. G., Lee, W. H., Persson, C., Siponen, M. O., Nilsson, M., Busam, R. D., 
. . . Lehtio, L. (2011). Comparative structural analysis of lipid binding 
START domains. PLos One, 6(6), e19521. 
Todd, R., & Wong, D. T. (1999). Oncogenes. Anticancer Research, 19(6A), 4729-
4746. 
 70 
 
Tonus, C., Sellinger, M., Koss, K., & Neupert, G. (2012). Faecal pyruvate kinase 
isoenzyme type M2 for colorectal cancer screening: A meta-analysis. World 
Journal of Gastroenterology, 18(30), 4004-4011. 
Triantafillidis, J. K., Nasioulas, G., & Kosmidids, P. A. (2009). Colorectal cancer 
and inflammatory bowel disease: Epidemiology, risk factors, mechanisms of 
carcinogenesis and prevention strategies. Anticancer Research, 29(7), 2727-
2737. 
Tsujii, M., Kawano, S., Tsujii, S., Sawaoka, H., Hori, M., & Dubois, R. N. (1998). 
Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell, 
93(5), 705-716. 
Ullmannova, V., & Popescu, N. C. (2006). Expression profile of the tumor 
suppressor genes DLC-1 and DLC-2 in solid tumors. International Journal of 
Oncology, 29(5), 1127-1132. 
Valencia, A., Chardin, P., Wittinghofer, A., & Sander, C. (1991). The ras protein 
family: Evolutionary tree and role of conserved amino acids. Biochemistry, 
30(19), 4637-4648. 
Van Troys, M., Huyck, L., Leyman, S., Dhaese, S., Vandekerkhove, J., & Ampe, C. 
(2008). Ins and outs of ADF/cofilin activity and regulation. European 
Journal of Cell Biology, 87(8-9), 649-667. 
Varmeulen, K., Van Bockstaele, D. R., & Berneman, Z. N. (2003). The cell cycle: A 
review of regulation, deregulation and therapeutic targets in cancer. Cell 
Proliferation, 36(3), 131-149. 
Vega, F. M., & Ridley, A. J. (2008). Rho GTPases in cancer cell biology. FEBS 
Letters, 582(14), 2093-2101. 
Viallet, J., & Minna, J. D. (1990). Dominant oncogenes and tumor suppressor genes 
in the pathogenesis of lung cancer. American Journal of Respiratory Cell and 
Molecular Biology, 2(3), 225-232. 
Vivanco, I., & Sawyers, C. L. (2002). The phosphatidylinositol 3-Kinase AKT 
pathway in human cancer. Nature Reviews. Cancer, 2(7), 489-501. 
Vogelstein, B., & Kinzler, K. W. (2004). Cancer genes and the pathways they 
control. Nature Medicine, 10(8), 789-799. 
Wang, Y., & Mc Niven, M. A. (2012). Invasive matrix degradation at focal 
adhesions occurs via protease recruitment by a FAK-p130Cas complex. 
Journal of Cell Biology, 196(3), 375-385. 
Wasserberg, N., & Kaufman, H. S. (2007). Palliation of colorectal cancer. Surgical 
Oncology, 16(4), 299-310. 
Watson, A. J., & Collins, P. D. (2011). Colon cancer: A civilization disorder. 
Digestive Diseases, 29(2), 222-228. 
 71 
 
Wennerberg, K., & Der, C. J. (2004). Rho-family GTPases: It's not only Rac and 
Rho (and I like it). Journal of Cell Science, 117(Pt 8), 1301-1312. 
Wolfenson, H., Henis, Y. I., Geiger, B., & Bershadsky, A. D. (2009). The heel and 
toe of the cell's foot: A multifaceted approach for understanding the structure 
and dynamics of focal adhesions. Cell Motility and the Cytoskeleton, 66(11), 
1017-1029. 
World Health Organization. (2010, February 4). Cancer statistics. World Health 
Organization. Retrieved from 
http://www.who.int/cancer/detection/colorectalcancer/en/ 
Worthylake, R. A., & Burridge, K. (2003). RhoA and ROCK promote migration by 
limiting membrane protrusions. The Journal of Biological Chemistry, 
278(15), 13578-13584. 
Wu, M., Wu, Z., Rosenthal, D. T., Rhee, E. M., & Merajver, S. D. (2010). 
Characterization of the roles of RhoC and RhoA GTPases in invasion, 
motility, and matrix adhesion in inflammatory and aggressive breast cancers. 
Cancer, 116(11 Suppl), 2768-2782. 
Xiaorong, L., Wei, W., Liyuan, Q., & Kaiyan, Y. (2008). Underexpression of deleted 
in liver cancer 2 (DLC2) is associated with overexpression of RhoA and poor 
prognosis in hepatocellular carcinoma. BioMed Central Cancer, 23(8), 205-
211. 
Xie, J., & Itzkowitz, S. H. (2008). Cancer in inflammatory bowel disease. World 
Journal of Gastroenterology, 14(3), 378-389. 
Yamaguchi, H., Lorenze, M., Kempiak, S., Sarmiento, C., Coniglio, S., Symons, M., 
. . . Condeelis, J. (2005). Molecular mechanisms of invadopodium formation: 
The role of the N-WASP-Arp2/3 complex pathway and cofilin. The Journal 
of Cell Biology, 168(3), 441-452. 
Yarbro, J. W., Page, D. L., Fiedling, P. L., Partridge, E. E., & Murphy, G. P. (1999). 
American Joint committee on cancer prognostic factors consensus 
conference. Cancer, 86(11), 2436-2446. 
Yin, L., Grandi, N., Raum, E., Haug, U., Arndt, V., & Brenner, H. (2011). Meta-
analysis: Serum vitamin D and colorectal adenoma risk. Preventive medicine, 
53(1-2), 10-16. 
Yokota, J. (2000). Tumor progression and metastasis. Carcinogenesis, 21(3), 497-
503. 
Zamir, E., & Geiger, B. (2001). Molecular complexity and dynamics of cell-matrix 
adhesions. Journal of Cell Biology, 114(Pt 20), 3583-3590. 
Zhou, F. Q., & Sinder, W. D. (2006). Intracellular control of developmental and 
regenerative axon growth. Philosophical Transactions of the Royal Society of 
Biological Sciences, 361(1473), 1575-1592. 
